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Conventional drug susceptibility testing techniques, the ‘gold standard’ for M. 
tuberculosis are slow, requiring about 3-6 weeks from a positive culture. This 
diagnostic delay, before initiation of appropriate treatment, contributes to increased 
transmission rates. Molecular techniques provide rapid results and therefore present 
an alternative to conventional tests. The aim of this project was to develop an in-
house reverse line blot hybridization assay (RIFO assay) that could detect mutations 
associated with Rifampicin resistance directly in clinical specimens of patients in 
KwaZulu Natal.  
 
A 437 bp region of the rpoB gene was sequenced to ascertain the most frequently 
occurring mutations conferring resistance to rifampicin in isolates in KwaZulu-Natal. 
Wildtype and mutant probes designed to target these mutations, were immobilized on 
a Biodyne C membrane. Hybridization conditions were optimized using biotin labeled 
PCR products from culture. Detection was performed with peroxidase labeled 
streptavidin using enhanced chemiluminescence. Four DNA extraction methods were 
evaluated on sputum specimens to determine the one with the least inhibitory effect 
on amplification.  
 
A total of 11 mutations were found in 236 clinical isolates: 531TTG (109, 58.3%), 
516GTC (26, 13%), 533CCG/516GGC (20, 10%), 533CCG (18, 9.6%), other 
mutations < 5% each. The chelex extraction method was found to be optimal for 
removing inhibitors in sputum specimens. Sputum specimens of 404 patients 
hospitalized at King George V Hospital between 2005 and 2006 were rifoligotyped. 
 xviii 
The RIFO assay was optimised on clinical isolates and then applied to sputum 
specimens. The RIFO assay on culture and sputum correlated well with the DST 
(sensitivity 92% and 94% respectively). However, the specificity was very low in 
both culture and sputum specimens compared to DST (38% and 35% respectively). 
This could be attributed to the presence of silent mutations, mixed infections, mixed 
populations of bacteria or the small number of susceptible strains used in this study.  
 
The in-house RIFO assay can be used directly on sputum specimens to predict 
Rifampicin resistance and therefore MDR-TB in less than a week compared to the 
gold standards. A total of 43 samples can be tested simultaneously at low cost and the 
membrane is reusable compared to commercial kits such as the Hains test that is 
expensive and strips are not reusable. A similar assay can be designed to target 
mutations for the detection of XDR-TB. Future studies should be conducted in a 
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Although effective anti-tuberculosis (TB) drugs have been available for decades in South 
Africa, TB is still a major problem. Drug resistance, an outcome of non-compliance with 
drug intake, has been known to be the most significant limitation for the success of TB 
treatment (Mahmoudi and Iseman, 1993). The recent emergence of extensive drug 
resistance has greatly increased the significance of rapid susceptibility testing of 
Mycobacterium tuberculosis strains (Pillay and Sturm, 2007). Current methods used in 
susceptibility testing are slow, resulting in delays, which make it difficult to administer 
appropriate treatment timely. This is one of the most important aspect contributing to the 
transmission of TB, including multi-drug resistant (MDR) outbreaks and more 
specifically, extensively drug resistant (XDR) TB.  
 
During the 1990’s, MDR-TB defined as resistance to Isoniazid (INH) and Rifampicin 
(RIF) (WHO, 1997), was considered to be a threat to TB control. However, emergence of 
the XDR TB cases has aggravated the situation, raising fear of a future epidemic of 
untreatable TB (CDC, 2006). New anti-TB drug regimens, improved diagnostic tests, and 
standardised second line drug susceptibility testing, are needed for rapid detection and 
effective treatment of drug resistant TB (CDC, 2006). However, with the slow growth 
rate of M. tuberculosis, culture requires weeks or even months to obtain results 
(Kingsbury et al, 1985). Patients that harbour infection for weeks or months while they 
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receive ineffective treatment while awaiting susceptibility test results, transmit TB. Such 
delays in susceptibility tests increase the risk of transmission both in the community and 
in hospitals. It is crucial to detect drug resistance timeously in clinical isolates of M. 
tuberculosis for administering of appropriate treatment to avert the development of 
further resistance and the spread of resistant strains. Identification of these strains is of 
paramount importance as it can allow initiation of modified treatment regimens. This will 
impact positively on both public health and patient outcome by reducing the spread of 
drug resistant strains. 
 
RIF is one of the most potent first line anti-TB drugs (WHO, 1997). Its resistance heralds 
a more prolonged treatment for the patient and poor results if the isolate is also resistant 
to INH (Mitchison and Nunn, 1986). The presence of RIF resistance increases the 
likelihood of MDR-TB because M. tuberculosis strains resistant to RIF are more likely to 
be resistant to several other anti-TB drugs (Telenti et al, 1993, Morris et al, 1995). The 
mechanism of RIF resistance is well characterised and has led to the development of 
molecular assays for rapid detection of RIF resistance (Telenti et al, 1993; Kapur et al, 
1994; Williams et al, 1998; Cooksey et al, 1997; Nash et al, 1997; Piatek et al, 1998 and 
Torres et al, 2000). 
 
The occurrence of RIF monoresistance is rare and more than 90% of RIF-resistant 
isolates are also resistant to INH (Heep et al, 2000). Therefore RIF is a good marker of 
MDR-TB, and thus can be used as a predictor of MDR-TB (Cole and Telenti, 1995; 
Drobniewski and Wilson, 1998; Ramaswamy and Musser, 1998). Ninety-five percent of 
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RIF resistant isolates of M. tuberculosis harbour specific mutations within the 81-bp 
region of the RNA polymerase (Yamada et al, 1985, Telenti et al, 1993). The presence of 
these mutations can be detected by a genetic assay and could predict clinical drug 
resistance in the majority of patients.  
 
While RIF is associated mainly with single point mutations in one region of the RNA 
polymerase gene (rpoB) that can easily be amplified by PCR methods, in contrast INH 
drug resistance is more complex. It involves mutations in at least four gene complexes 
and not all mutations result in an alteration of the wild type phenotype (Zhang et al, 1992; 
Barnerjee et al, 1994; Heym et al, 1995; Drobniewski and Wilson, 1998). Therefore, 
development of an assay for the detection of mutations involved in INH resistance is 
more complicated and makes detection of RIF resistance more convenient compared to 
INH resistance.  
 
Detection of mutations is more rapid than conventional RIF susceptibility testing, which 
depends on culture and therefore, requires an additional 3 to 6 weeks after the primary 
isolation to obtain the results. Early detection of MDR-TB can improve treatment 
outcome for the individual patient and reduce the opportunity for spread of the infection. 
Since RIF resistance is considered the surrogate marker for the identification of MDR-TB 
(CDC, 1993; Bloch et al, 1994), it would be useful for poorly resourced countries to have 




The objectives of this study were three-fold: 
 
(i) to identify the rpoB mutations associated with RIF resistance in a 
panel of isolates of M. tuberculosis isolated in KwaZulu-Natal (KZN), 
South Africa, 
 
(ii) to determine the optimal method of DNA extraction resulting in the 
fewest or no PCR inhibitors and highest sensitivity in PCR based 
techniques to be used. 
 
(iii) to optimize and evaluate the reverse line blot assay, rifoligotyping or 
RIFO assay for the identification of RIF resistance that is based on 
PCR amplification of the rpoB gene and the detection of the 
commonest mutations in KZN.   
 
We hypothesize that the optimised rifoligotyping assay will be able to detect mutations in 
the rpoB gene directly in sputum specimens and this will serve as a marker of RIF 




2. LITERATURE REVIEW 
 




The tubercle bacillus belongs to the genus Mycobacterium, of the family 
Mycobacteriaceae (Shinnick, 1996). The M. tuberculosis complex includes five species 
of mycobacteria which can cause tuberculosis (TB): M. africanum, M. bovis, M. canetti 
and M. microti and M. tuberculosis. The first two rarely cause disease in humans; the 
second two do not cause human disease while the last is the major cause of the disease 
TB in humans. Although for many years TB complex organisms were known to grow 
aerobically, (Shinnick, 1996), it has been also shown to persist in conditions of hypoxia 
(Wayne and Sohasky, 2001). TB is predominantly the disease of the lungs but it can also 
affect bones and joints, vascular system, central nervous system, genitourinary systems 
and the lymphatic system (Salerno et al, 2006).  
 
2.1.2. GROWTH AND PHYSICAL CHARACTERISTICS 
 
M. tuberculosis is a slow growing microbe with generation times ranging from 12-24 
hours (Iseman, 2000). This is extremely slow compared to other bacteria, which tend to 
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have division times measured in minutes. It is primarily a facultative, intracellular 
pathogen which resides within the phagolysosomes of alveolar macrophages (Shinnick, 
1996). M tuberculosis is typically slightly curved or straight rod shaped. Its typical size 
when cultured in vitro is 1 to 4 mm in length and 0.3 to 0.6 mm in diameter, making it 
smaller than most bacterial pathogens (Iseman, 2000).  
 
2.1.3. MICROSCOPIC CHARACTERISTICS 
 
M. tuberculosis is an acid-fast bacillus (AFB). AFB are gram positive bacilli that stain 
poorly and are seldom seen in a gram stain. This is due to the lipid content of their cell 
wall. The primary cell wall structure of M. tuberculosis consists of a plasma membrane, 
which is supported by a peptidoglycan backbone against the osmotic pressure of the 
interior (Shinnick, 1996). Attached to the peptidoglycan is an arabinogalactan layer and 
to which are esterified mycolic acids. The high lipid content of M. tuberculosis cell wall 
makes it highly hydrophobic, which results in the clumping of cells, a characteristic that 
prevents staining with the usual chemicals. 
 
M. tuberculosis can be identified microscopically by its staining characteristics. It resists 
decolorisation with acid after being stained. In the most common staining technique, the 
Ziehl-Neelsen stain, AFB are stained a bright red which stands out clearly against a blue 
background (Figure 2.1). AFB can also be visualized by fluorescent microscopy using an 
auramine-rhodamine stain. The mycobacterial cell wall is impermeable towards many 









2.1.4. TRANSMISSION OF TB 
 
Transmission of TB begins after contact with a human source, almost always an 
infectious person with cavitary pulmonary TB. The infection is transmitted almost 
exclusively by the airborne route via a small bacillus-containing particle called a droplet 
nucleus (Iseman, 2000). When a droplet nucleus containing one or two viable bacilli is 
inhaled, it is deposited on the alveolar surface where the bacilli begin to multiply. 
Initially, the infecting organism meets only limited resistance from the host, as 
phagocytosis by alveolar macrophages has little effect on the bacilli. The earliest 
evidence of host tissue recognition is dilation of the capillaries, followed by a migration 




weeks of infection, the number of leukocytes in the area decreases and the mononuclear 
cells predominate. These crowd together and contain pale, foamy cytoplasmic material, 
which is rich in lipids. The resulting unit is called a tubercle, the fundamental lesion of 
TB (Shinnick, 1996). 
 
When an individual is infected with the tubercle bacilli, the organism is taken up by the 
alveolar macrophages and carried to the lymph nodes. In the lymph nodes it can spread 
further to other organs. It takes about 2 to eight weeks after infection for the immune 
system to elicit a response. During this time, cell mediated immunity and hypersensitivity 
develops which leads to the characteristic reaction of the tuberculin test (Houben et al, 
2006). In immunocompetent individuals containment of infection then follows.  
 
About 10% of these infected individuals will develop active disease in their lifetime. The 
other 90% do not become ill and cannot transmit the organism due to the ability of the 
normal immune system to contain the infecting organism or even in some instances, to 
eradicate them. Individuals who are taking immunosuppressive agents or those that are 
infected with Human Immunodeficiency Virus (HIV) are more likely to develop the 
disease because of their compromised immunity. Therefore, TB is reported to be rampant 
in populations that have dual infections with HIV (Barnes et al, 1991). 
 
 9 
2.2. EPIDEMIOLOGY OF TB 
 
2.2.1.  TB INCIDENCE AND PREVALENCE 
 
The World Health Organisation (WHO) estimated that there were 9.4 million incident 
cases (8.9-9.9 million) of TB globally in 2009 (WHO, 2010). Most of the estimated 
number of cases occurred in Asia (55%) and Africa (30%), smaller proportions occurred 
in the Eastern Mediterranean Region (7%), the European region (4%) and the Region of 
the America’s (3%) (Figure 2.2) (WHO, 2010). South Africa is one of the 5 countries 
with a high burden of incident TB (0.40-0.59 million cases).  
 
Globally, there were an estimated 14 million prevalent cases (12 million- 16 million) of 




Figure 2.2 Estimated TB incidence rates by country (WHO, 2010) 
 
2.2.2. MDR AND XDR TB 
 
There were an estimated 440 000 cases of MDR TB in 2008 (390 000- 510 000). South 
Africa is one of the four countries that had the largest number of estimated cases of MDR 
TB in absolute terms in 2008 (13 000; 10 000-16 000). It is estimated that South Africa 
had 1.8% MDR among new TB cases and 6.7% amongst previously treated TB cases and 
10.5% of XDR cases (WHO, 2010)  
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2.3. HISTORICAL OVERVIEW OF TB TREATMENT  
 
The treatment of TB goes as far back as the late eighteenth century. However, it was the 
discovery of streptomycin from Streptomyces griseus by Selman Waksman and his 
colleagues in 1943 that saw the birth of a new era of chemotherapeutic approach to TB 
therapy or treatment (Keers, 1978). Although streptomycin proved to inhibit the growth 
of M. tuberculosis, it soon became apparent that resistant mutants thrived in the 
application of streptomycin monotherapy, resulting in treatment failure.  
 
The quest for new drugs to treat TB subsequently lead to the discovery of p-
aminosalicylic acid (PAS) in 1949, isoniazid (INH) in 1952, pyrazinamide (PZA) in 
1954, cycloserine in 1955, ethambutol (EMB) in 1962, and rifampicin (RIF) in 1963 
(Rattan et al, 1998). In years to follow, more drugs were discovered, such as 
aminoglycosides which include capreomycin (CAP), viomycin (VIO), kanamycin (KM), 
amikacin (AK) and quinolones such as ofloxacin (OFX) and ciprofloxacin (CIP) (Rattan 
et al, 1998). Currently, the use of INH, EMB, STR, PZA and RIF constitute the first line 
drugs for the treatment of TB (Rattan et al, 1998). The proper use of these drugs should 
produce a rapid clinical improvement and a significant decrease in bacterial count (WHO, 
1997). 
 
The TB treatment regimen comprises of two phases: the intensive and the continuation 
phase. The intensive phase takes two months and involves multiple antibiotics such as 
RIF, INH, PZA and EMB or STR, to ensure that mutants resistant to a single drug do not 
emerge (WHO, 1997).  The following 4 months is the continuation phase and only RIF 
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and INH are administered to eliminate any uncleared tubercle bacilli. INH and RIF are 
the two most potent anti-TB drugs and kill more than 99% of tubercle bacilli within 2 
months of initiation of therapy (Mitchison, 1985; Iseman, 1989). Therefore, resistance to 
these two drugs was regarded as MDR in M. tuberculosis (WHO, 1997). The use of these 
drugs in conjunction with each other reduces antitubercular therapy from 18 months to 6 
months. When TB results from infection with drug susceptible strains of M. tuberculosis, 
the success rate of this treatment is close to 100%, provided that the patient strictly 




RIF, derived from Streptomyces mediterranei was first introduced for use as 
antitubercular therapy in the early 1970’s and is still a very important component of 
current regimens (Musser, 1995). It is the most potent sterilizing antibiotic used for the 
treatment of TB (Goble et al, 1993). The mode of action of RIF is based on the inhibition 
of the elongation of transcripts by covalently binding to the beta subunit of RNA 
polymerase in M. tuberculosis thus leading to bacterial death (Miller et al, 1994). The 




Isoniazid, also called isonicotinic acid hydrazide (INH) was first synthesised in the early 
part of the 19th century but only introduced as anti-TB drug in the 1950’s (Ramaswamy 
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and Musser, 1998) and its powerful anti-TB activity was discovered in 1951. INH used in 
treatment of TB is a prodrug and necessitates catalytic activation by KatG to be converted 
into the active form. KatG is an enzyme with dual activities of catalase and peroxidase 
(Lei et al, 2000). Catalase-peroxidase is a heme containing enzyme encoded by the katG 
gene of M. tuberculosis (Zhang et al, 1992), which converts INH to a toxic derivative. 
INH activation leads to inhibition of mycolic synthesis, a long chain fatty acid-containing 
component of the mycobacterial cell wall (Winder and Collins, 1970; Takayama et al, 
1972). Two enzymes involved in the elongation cycle of the fatty acid biosynthesis, 
namely an enoyl-acyl carrier protein reductase (Banerjee et al, 1994) and β-ketoacyl-acyl 





EMB is a first line M. tuberculosis drug with a broad spectrum of activity. Takayama and 
Kilburn in 1989, demonstrated that the cell wall, and more specifically mycolic acid 
synthesis process, is the primary target of EMB. They observed effects such as the 
inhibition of the transfer of precursor molecules in mycolic acid synthesis from the 
cytoplasm to the cell wall (Takayama et al, 1979), the accumulation of the trehalose-, 
mon- and dimycolates in the cell and the inhibition of the synthesis of arabinogalactan 
from D-arabinose (Kilburn and Takayama, 1981). Other investigators have suggested that 
the inhibition of glucose metabolism may be involved (Silve et al, 1993). A resistant 
mutant of M. tuberculosis contained less phospholipids and unsaturated fatty acids and 
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more arabinose, galactose, hexosamine and mycolic acids than the EMB susceptible 





STR is a broad spectrum antibiotic of the aminoglycoside family that is bactericidal in 
action and was the first drug used in treatment of TB. It is an aminocyclitol glycoside that 
interferes with prokaryotic protein synthesis. Its main effects are induction of misreading 
of the genetic code and inhibition of initiation of translation (Moazed and Noller, 1987). 
The site of action of streptomycin is the small 30s, subunit of the ribosome, especially the 
ribosomal protein S12 and the 16S rRNA (Garvin et al, 1974). STR acts at several stages 
in protein synthesis and its main effects appear to be the inhibition of initiation of mRNA 
translation, misreading of genetic code and aberrant proofreading by bacterial ribosome.  
 
2.3.5. PYRAZINAMIDE  
 
Currently, PZA is one of the essential drugs in short course chemotherapy of TB. PZA is 
a synthetic derivative of nicotinamide that has been used in short course anti-TB 
treatment regimens (Musser, 1995).  This drug is the least studied of all the drugs of 
treatment because its activity depends upon an acid pH environment which leads to 
discrepancies between the in vivo and in vitro investigations. It acts in the acidic 
extracelluar micro-environment found during acute inflammation and kills at least 95% of 
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bacilli during the first two weeks of treatment (Mitchison, 1985). The target of action of 
PZA in M. tuberculosis is thought to be fasI (Zimhony et al, 2000). It is known that M. 
tuberculosis converts PZA to its active form, pyrazinoic acid, by using enzyme 
pyrazinamidase (PZAse) (Konno et al, 1967). 
   
2.4. GENETIC MECHANISMS OF RESISTANCE  
 
Generally, resistance arises by the process of mutation and adaptation. In M. tuberculosis 
drug resistance occurs spontaneously i.e. sites for resistance are chromosomally located 
and not linked (Iseman, 2000). It differs from most other bacteria in its cell wall 
composition, and as a result exchange of genes across this cell wall is difficult. 
Acquisition of drug resistance in M. tuberculosis does not involve plasmids or 
transposable elements. However, drug resistance is an outcome of changes in protein 
structure involved in drug uptake or in activation of prodrugs (Middlebrook et al, 1954, 
Telenti et al, 1993; Takayama et al, 1979, Kilburn and Takayama, 1981). These changes 
are due to mutations in genes coding for such proteins. The mutations that occur 
randomly at chromosomal loci include nucleotide changes such as point mutations, small 
deletions or insertions which confer resistance to single drugs. M. tuberculosis 
accumulates these mutations in a stepwise manner and this leads to drug resistant TB. 
Drug resistant strains also emerge when treatment is discontinued or otherwise 
insufficient, emphasizing the importance of early detection of drug resistance.  
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Resistant organisms (or mutants) evolve in the absence of drug exposure but they are 
diluted within the vast majority of the drug-susceptible bacilli. During bacterial 
multiplication, resistance develops through spontaneous mutations at a defined rate e.g. 
mutations resulting in resistance to RIF occurs at a rate of 10-8 in M. tuberculosis in vitro 
and is thought to be a one step mutational event (Tsukamura, 1972, Iseman et al, 1989, 
Musser, 1995). For INH and EMB, resistance rate occurs at a rate 10-6 and for STR 10-5 
(Musser, 1995). During antibiotic treatment, the susceptible sub-population of bacilli are 
killed and allow the resistant mutants to be selected.  
 
 
Table. 2.1 Genetic loci conferring drug-resistance in Mycobacterium tuberculosis  
 
Drug Gene Product Frequency of mutations 
in resistant strains (%) 
Rifampicin rpoB B-subunit of 
RNA polymerase 




 inhA Enoyl-ACP 
reductase 
< 10 
 ahpC-oxyR Alky hydro-
reductase 
~ 20 
Streptomycin rpsL Ribosomal 
protein S12 
60 
 rrs 16s rRNA < 10 
Pyrazinamide pncA Amidase 70-100 
Ethambutol embB EmbCAB 69 
Table from Rattan et al, 1998 
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2.4.1. RESISTANCE TO FIRST LINE DRUGS 
 
2.4.1.1. RIF RESISTANCE 
 
Resistance to RIF has been shown to be due to the alteration of the beta subunit of the 
RNA polymerase encoded by the rpoB gene (Telenti et al, 1993). Several authors have 
reported specific mutations, insertions, and deletions in this gene (Telenti et al, 1993; 
Williams et al, 1998; Yuen et al, 1999). About 96% of RIF resistant isolates of M. 
tuberculosis have point mutations in an 81-bp region of this gene. These mutations are 
not present in susceptible isolates and are thus an ideal target for development of genetic 
susceptibility testing methods (Telenti et al, 1993). Mutations in the rpoB gene lead to an 
altered structure of RNA polymerase and hence to a largely impaired affinity to RIF for 
this enzyme (Musser, 1995).  
 
2.4.1.2. INH RESISTANCE 
 
Complex metabolic changes have been described for INH resistant organisms. Resistance 
to this drug is associated with a range of mutations affecting one or more genes such as 
those encoding catalase-peroxidase (katG) (Zhang et al, 1992; Cockerill et al, 1995), the 
two gene operon (inhA locus) encoding the enoyl-acyl carrier protein reductase involved 
in mycolic biosynthesis (Banerjee et al, 1994), the alkyl hydroperoxidase reductase 
(ahpC), which is involved in the cellular response to oxidative stress (Wilson and Collins, 
1996; Kelley et al, 1997), the β-ketocyl acyl carrier protein synthase (kasA) which is 
important in fatty acid elongation (Mdluli et al, 1998) and the ndh gene which encodes an 
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NADH dehydrogenase, causing defects in the enzyme activity that results in an increased 
NADH/NAD+ ratio and co-resistance to INH and ethionamide (Lee et al, 2001). 
However, most studies have demonstrated that INH is most frequently associated with 
mutations in katG gene.  
 
2.4.1.3. EMB RESISTANCE 
 
Resistance to EMB is a result of mutations in the embB gene, coding for arabinosyl 
transferase, which is involved in mycolic acids metabolism (Takayama et al, 1979). The 
substitutions on codon 306 in the M. tuberculosis gene embB have been shown to be the 
most frequent and most predictive mutations for EMB resistance (Sreevatsan et al, 1998).   
 
2.4.1.4. STR RESISTANCE 
 
Resistance to STR has been shown to result from three different mechanisms. Firstly, the 
S12 protein is encoded by the rpsL gene and missense mutations in this gene have been 
shown to confer STR resistance. Presence of mutations results in changes in the 
conformational structure of the ribosomal subunits. This affects the binding of STR to the 
ribosome and as a result, the effects of the drug when bound are diminished (Meier et al, 
1994). Secondly, resistance occurs due to changes in the 16S rRNA (Finken et al, 1993). 
This protein is encoded by the rrs gene and mutations in this gene results in changes in 
the ribosomal structure. Isolates that do not possess mutations in these two genes are 
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believed to possess an alternate unknown mechanism of resistance (Yamada et al, 1985, 
Nair et al, 1993). 
 
2.4.1.5. PZA RESISTANCE 
 
Numerous investigations have reported that PZA-resistant organisms have lost the 
pyrazinamidase activity possessed by PZA susceptible strains (Scorpio and Zhang, 1996). 
Resistance to pyrazinamide is usually caused by mutations in the gene pncA encoding the 
enzyme pyrazinamidase (PZAse) (Butler and Kilburn 1983; Ramaswamy and Musser, 
1998). This enzyme metabolises PZA to pyrazinoic acid and PZA resistant organisms 
have lost PZAse activity (McClatchy et al, 1981; Butler and Kilburn, 1983). Therefore, it 
is suggested that PZA resistance may be a result of molecular mechanisms such as loss of 
PZAse structural gene or missense mutation resulting in an altered allele (Ramaswamy 
and Musser, 1998).  However, some highly PZA resistant strains do not always lack PZA 








2.5. SECOND-LINE DRUGS FOR TREATMENT OF RESISTANT TB 
 
2.5.1. FLUOROQUINOLONES (FQs) 
 
FQ therapy is associated with an improved outcome in MDR-TB. OFX and CIP have 
been shown to be the most active of the quinolone drugs against M. tuberculosis. OFX 
has been more frequently used compared to CIP because of its increased absorption and 
half life (Trimble et al, 1987). The primary target of FQs in many bacterial species is 
DNA gyrase which is involved in DNA replication (Hooper and Wolfson, 1993).  
 
2.5.2. CAPREOMYCIN AND VIOMYCIN  
  
CAP and VIO are mostly used together for treatment of drug resistance M. tuberculosis 
strains (Herr et al, 1966).  They are polypeptide antimicrobial agents and are structurally 
similar, such that cross-resistance between the two drugs in M. tuberculosis has been 
shown (MacClathy et al, 1977). CAP is a macrocyclic peptide antibiotic produced by 
Saccharothrix mutabolis subspecies capreolus (Sutton et al, 1966; Ziersky, 1969). This 
appears to hinder the process of translation in mycobacteria. It was shown to inhibit 
phenylalanine synthesis in an in vitro translation assay using mycobacterial ribosome’s 
(Trnka and Smith, 1970). CAP is very expensive but very useful in cases with tubercle 
bacilli resistant to STR, KM and AK. VIO affects the dissociation of the 70S ribosome of 
M. smegmatis subunit by binding to both the 30S and 50S ribosome subunits (Yamada et 
al, 1976). Furthermore, it inhibits ribosomal translocation by stopping peptidyl-tRNA in 
the ribosomal acceptor site (Modolell and Vazquez, 1977).  
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2.5.3. KANAMYCIN AND AMIKACIN 
 
KM is an aminoglycoside that is used in treatment of organisms that are resistant to first 
line drugs. KM is the least expensive, but largely used for indications other than TB in 
some countries.  Amikacin (AK) is as active as KM and better tolerated but much more 
expensive. KM and the closely related AK are commonly used for treatment of MDR-TB 
(Iseman, 2000). Although strains that acquire resistance to CAP also generally remain 




ETH, one of the most frequently used second-line drugs in the treatment of MDR TB and 
is a structural analog of INH (Blanchard, 1996). Both compounds are known to target the 
enoyl-acyl carrier protein reductase enzyme involved in biosynthesis of mycolic acid and 
is encoded by the inhA gene (Takayama et al, 1972). The structural similarity and 
existence of cross-resistant phenotypes suggests that ETH and INH share a common 





DCS is an effective antimycobacterial agent but is rarely prescribed and is seldomly used 
due to its adverse effects. Few studies have been conducted on the mode of action and 
mechanisms of DCS resistance in mycobacteria. It is believed that DCS inhibits the 
formation of peptidoglycan (David, 2001). It is also an inhibitor of D-alanine: D alanine 
branch (Lambert and Neuhaus, 1972) 
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2.6. DRUG SUSCEPTIBILITY TESTING IN M. tuberculosis 
 
Diagnostic mycobacteriology plays a significant role in the control of the spread of TB 
especially MDR-TB. Rapid methods of diagnosis and determination of drug susceptibility 
are particularly important. Conventional methods using solid media, either agar or egg-
based, require long incubation periods before the results are available. Rüsch-Gerdes et 
al, 1999 reported a significant reduction of turnaround times for susceptibility results 
(from 3-6 weeks to 3-15 days) as a result of introducing manual and automated methods 
for susceptibility testing in liquid media. 
 
2.6.1. SUSCEPTIBILITY TESTING USING SOLID MEDIA 
 
Three conventional methods that utilise solid media to determine whether an M. 
tuberculosis isolate is susceptible or resistant have been established, namely:  the absolute 
concentration method, the resistant ratio (RR) method and the proportion method 
(Drobniewski and Balabanova, 2002). 
 
2.6.1.1. ABSOLUTE CONCENTRATION METHOD 
 
Drug free media and media containing graded concentrations of the drug to be tested are 
inoculated with a standardised inoculum. The drug is included into solid agar or 
Lowenstein-Jensen medium or in broth as two-fold dilutions. Resistance is defined as the 
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lowest concentration of the drug that inhibits growth. The major limitation in this method 
is the variability in inoculum size (Vareldzis et al, 1994, Heifets, 1996). 
 
2.6.1.2. RESISTANCE RATIO (RR) METHOD 
 
This method is the refinement of the absolute concentration method that controls for 
variations in the Minimum Inhibitory Concentration (MIC) of a given isolate when tested 
on different batches of media containing drugs. It is defined as the MIC of the test isolate 
divided by the MIC of a standard susceptible strain such as H37Rv. Testing is conducted 
at three concentrations of the drug and is greatly affected by the inoculum size as well as 
the viability of the strains. In addition, any variation in the susceptibility of the control 
strain also affects the RR of the test strain (Vareldzis et al, 1994). 
 
2.6.1.3. PROPORTION METHOD 
 
The proportion method based on culture is the ‘gold standard’ for the detection of 
resistance in M. tuberculosis isolates (Canetti, 1965). In this method, the isolate is 
classified as susceptible below a critical proportion of resistant bacteria and as resistant 
above it. The proportion of drug resistant mutants in a population is calculated from a 
ratio of the number of colonies growing in drug containing medium and on drug free 
medium (Vareldzis et al, 1994). It is an inexpensive and relatively simple technique, 
which provides results in 3 weeks from a cultured isolate or from AFB smear positive 
sputum specimen. 
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2.6.2. SUSCEPTIBILITY TESTING USING LIQIUD MEDIA 
 
It is widely known that drug susceptibility testing of M. tuberculosis is more rapid in 
liquid compared to solid media.  Liquid media systems use an increase in biomass as a 
growth marker of TB and hence predicting resistance to the drug by the test organism. 
Radiometric methods were first introduced in mycobacteriology by Cummings et al, 
1975. A major advancement was made in 1977, when Middlebrook introduced a liquid 
7H12 medium containing 14C-labelled palmitic acid for radiometric detection of 
mycobacterial growth (Middlebrook et al, 1977).  
 
2.6.2.1. BACTEC 460 TB METHOD  
 
The BACTEC 460 method is a radiometric variant of the proportion method and was first 
described by Siddiqi et al, in 1981. The method is based on detection of growth 
radiometrically. During growth, bacteria utilize a radiolabelled source of carbon (14C) and 
produces radiolabeled CO2. The instrument records the level of radioactivity as growth 
index. This method has shortened the duration of susceptibility testing to 5 to 7 days. The 
BACTEC system provides results in only 5 days but it is costly and requires disposal of 
radioactive material. In 1983, Roberts et al reported 98% agreement for BACTEC 460TB 
in comparison with conventional susceptibility testing of M. tuberculosis with a 
turnaround time of approximately 5 days. These results were concordant with those of 
Siddiqi et al (1981).   
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2.6.2.2. MYCOBACTERIA GROWTH INDICATOR TUBE (MGIT) 
METHOD 
 
 Palaci et al, (1996) reported the Mycobacteria Growth Indicator Tube (MGIT) to be time 
saving, safe, simple and reliable in the detection of drug resistance. The method uses 
tubes containing 4.0 ml of Middlebrook 7H9 broth with an oxygen sensitive fluorescence 
sensor embedded in silicone to indicate microbial growth. The broth is enriched 7H9 
(modified Middlebrook) broth base with 0.25% glycerol and 10% CO2 (Walters and 
Hanna, 1996).  
 
Actively respiring mycobacteria use the oxygen available within the tube, thereby 
exciting the fluorescence reaction. In the presence of oxygen the fluorescent indicator is 
quenched. Fluorescence indicating mycobacterial growth is then detected when the MGIT 
is viewed with a 365-nm ultraviolet (UV) light from transilluminator.  Antimycobacterial 
susceptibility testing can be performed by comparing the growth in an antibiotic-
containing MGIT with that of a growth control MGIT without antibiotics (Walters and 
Hanna, 1996).  
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2.6.2.3. MB/BacT SYSTEM   
  
The MB/BacT system has been reported to be a rapid, sensitive method for the growth 
and detection of mycobacteria from clinical specimens and has shown good performance 
in comparison with BACTEC 460 TB (Rohner et al, 1997; Brunello et al, 1999). In this 
closed system, mycobacterial growth is indicated by a colorimetric CO2 detection device. 
Unlike the BACTEC 460 TB, the cumbersome handling of bottles during incubation is 
avoided. Brunello and Fontana in 2000 concluded that MB/BacT system was suitable to 
test the antimicrobial susceptibility of M. tuberculosis to first line drugs. The advantage 
of this method is the absence of radioactivity when compared to BACTEC 460 TB 
method. 
 
2.6.3. MICROSCOPY BASED DRUG SUSCEPTIBILITY TESTING 
 
2.6.3.1. Microscopic observation Drug Susceptibility (MODS) Assay  
 
The simple microscopic observation drug susceptibility assay was developed by Caviedes 
et al, in 2000. This method uses the two properties of M. tuberculosis: (i) the growth rate 
of M. tuberculosis is rapid in liquid medium compared to the growth rate in solid 
medium, and (ii) its morphology in liquid culture is recognizable as consisting of tangles 
or cords of organisms. Middlebrook 7H9 broth inoculated with decontaminated sputum in 
24-well plates is examined under an inverted light microscope. Direct susceptibility 
testing on clinical specimens is performed by incorporating anti-TB drugs at the onset. 
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Park et al, 2002 and Moore et al, 2004 demonstrated similar results when comparing the 
MODS assay to gold standard proportion method showing a 100% agreement between 
the two methods.  
 
2.6.4. COLORIMETRIC METHODS 
 
Bacterial species have the ability to reduce an indicator and produce a change of visual 
colour. This has enabled researchers to exploit this characteristic to develop 
methodologies for DST such as the Alamar blue (Yajko et al, 1995; Franzblau et al, 
1998), MTT assay (Abate et al, 1998; Mshana et al, 1998; Foongladda et al, 2002), the 
nitrate reductase assay (Angeby et al, 2002), and resazurin (Palomino et al, 2002; Banfi 
and Monti-Bragadin, 2003). 
 
2.6.4.1. ALAMAR BLUE ASSAY 
 
Alamar blue is a dye that indicates cellular growth-viability due to the oxidation-
reduction process during metabolism of viable organisms. During metabolic activity the 
blue oxidised form becomes pink upon reduction. This method was first used by Pfaller et 
al (1994) for drug susceptibility testing of yeast and was first used on mycobacteria by 
Yajko et al (1995). Collins and Franzblau (1997) modified the assay format to create the 
microplate alamar blue assay or MABA. This assay has been used for DST of M. 




TETRAZOLIUM BROMIDE (MTT) 
 
MTT is a yellow tetrazolium salt that is converted into blue formazan by dehydrogenases 
of live cells (Mossman, 1983). The amount of blue or purple formazan formation is 
proportional to the number of live mycobacteria in a sample (Mshana et al, 1998). Abate 
et al (1998) and Moore et al (1998) applied this assay to detect RIF resistance directly 
from sputum specimens. They found it to shorten the turnaround time for detection of 
RIF resistance. 
 
2.6.4.3. NITRATE REDUCTASE ASSAY 
 
The nitrate reductase assay (NRA) was initially developed at the Central Tuberculosis 
Research Institute in Moscow Russia (Golyshevskaia et al, 1996). It was then called the 
Griess method, after J. P. Griess, who discovered the chemistry of the detection method 
(Griess and Bemerkungen, 1879). M. tuberculosis has the ability to reduce nitrate to 
nitrite and this is routinely used for biochemical identification of mycobacterial species. 
The presence of nitrite can easily be detected with specific reagents, which produce 
colour change (Kent and Kubica, 1985). Angeby et al (2002) evaluated this method for 
DST of M. tuberculosis and found it to be rapid, inexpensive and easy to perform. 
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2.6.4.4. RESAZURIN ASSAY 
 
The resazurin reduction test was first used to demonstrate bacterial and yeast 
contamination in milk (Khomenko and Matuzenko, 1976; Guerin et al, 2001).  Resazurin 
is a blue dye that does not flouresce but becomes pink and fluoresces as it is reduced to 
resofurin by oxidoreductases within live cells. This method produced the most reliable 
and accurate results for DST of INH and RIF (Palomino et al, 2002; Banfi and Monti-
Bragadin, 2003). It has been used for detection of both first line (Palomino et al, 2002) 
and second line antibiotic resistance of M. tuberculosis (Martin et al, 2003) 
 
2.7. MOLECULAR TECHNIQUES 
  
Molecular drug assays can be divided into phenotypic and genetic assays. Phenotypic 
assays are based on measuring an outcome e.g. death of the bacillus and do not require 
prior knowledge of the primary resistance mechanism. Genotypic assays are based on 
understanding the drug target and nature of the gene involved in the mechanism of 
resistance. 
 
2.7.1. PHENOTYPIC MOLECULAR TECHNIQUES 
 
Phenotypic molecular methods use markers of viability instead of an increase in 
biomass as in the case of liquid media based susceptibility testing. Anti-TB drugs also 
inhibit bacterial metabolic activities in susceptible isolates but not in resistant isolates. 
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Strategies for the detection of resistance that have been used include 
mycobacteriophages such as the phage assay (Albert et al, 2002; Galí et al, 2003) and 
the luciferase reporter phages (LRPs) (Jacobs et al, 1993). Drug susceptibility is 
assessed without reference to the genetic basis of resistance.  
 
2.7.1.1. PHAGE ASSAY 
 
The phage assay is fast and easy to perform, yielding results in clinical specimens within 
48 hours (Albert et al, 2002; Krishnamurthy et al, 2002). Bacteriophages can infect and 
replicate inside mycobacteria. Once mycobacteria are infected, the number of internalised 
phages determined indicates the original number of M. tuberculosis. This is determined 
after a number of cycles of infection, replication and release in rapidly growing 
mycobacteria such as M. smegmatis.  
 
When drug resistant M. tuberculosis is infected with a mycobacteriophage, it remains 
viable and protected within the bacilli. It then replicates within viable bacilli and 
eventually lyses its host and lysis is easily seen as clear areas or plaques in a lawn of M. 
smegmatis culture. The number of plaques generated is directly proportional to the 
number of protected mycobacteriophages, which is dependent on the number of tubercle 
bacilli that remain viable after drug treatment (Gingeras et al, 1998). The sensitivity of 
this assay as well as the presence of inhibitors in sputum poses major problems. 
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2.7.1.2. LUCIFERASE REPORTER ASSAY (LRP) 
 
Jacobs et al (1993) demonstrated that luciferase reporter mycobacteriophages can be used 
as a simple tools for rapid determination of drug susceptibility profiles of M. tuberculosis. 
Luciferase activity can be monitored with a luminometer or with a photographic film. 
The luminometer offers higher sensitivity and quantitative results in 54 hours. It is based 
on the efficient production of photons by viable mycobacteria infected with specific 
reporter phages expressing the firefly luciferase gene (lux). Some reporter phages possess 
the firefly gene. Riska et al  (1999) reported that these phages can inject their lux bearing 
genes in viable mycobacteria and this would result in production of photons. The injected 
lux gene, when transcribed, using the mycobacterial ATP, catalyses the production of 
light. This activity can be detected by using the luminometric instrument. Mycobacterial 
cells killed by anti-TB drugs can not be infected and thus do not produce light. 
 
The shortcoming of this assay is that the mycobacteriophage has a broad host array and 
will infect many non-tuberculous mycobacteria and therefore may lead to false positive 
reports of drug resistant M. tuberculosis. Although there are techniques for increasing 
species specificity for this assay, this comes at great cost and complexity. This procedure 
has shown promising results with clinical isolates and sputum samples (Banaiee et al, 
2001; Bardorov et al, 2003). Photographic detection is achieved by using the ‘Bronx 
box’, which is an expensive light tight box with a Polaroid cassette. This carries a 
photographic film which is able to detect light emitted by the infected cells carried out in 
microtiter plates. Qualitative results can be obtained in 94 hours.   
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2.7.2. GENETIC MOLECULAR TECHNIQUES 
 
The genes coding for the targets of the first-line anti-tuberculosis drugs as well as the 
mutations associated with the resistant phenotypes have been identified. The detection of 
these mutations is facilitated since they are localised in limited regions of the genes 
encoding the drug targets. After PCR amplification, the mutation is identified by 
sequencing the PCR products or other mutation detecting methods. Molecular studies 
have indicated that the genome of M. tuberculosis, including mutations in the drug 
resistant genes, is stable in follow-up samples from MDR-TB patients (Victor et al, 
1997). This favours the use of molecular techniques to predict drug resistance by 
mutation analysis. Generally, resistance arises by a process of mutation and adaptation. 
Detection of genotypic drug resistance in M. tuberculosis isolates provides a rapid and 
easy alternative to conventional phenotypic susceptibility testing. 
 
MDR results from stepwise acquisition of mutations in the genes encoding drug targets or 
drug converting enzymes (Gillespie, 2002). This knowledge has paved the way for 
molecular assays that have potential to provide rapid detection of resistance in M. 
tuberculosis isolates. These techniques are highly sensitive, specific and the fact that they 
do not rely on mycobacterial growth has shortened the time between detection and the 
commencement of effective treatment. Genetic loci have been established as sources of 
resistance by targeting and sequencing these regions believed to be sources of resistance 
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to these drugs. Moreover, the genetic basis of resistance has been exploited to develop 
rapid tests for drug susceptibility.  
 
Molecular assays that have been used to monitor the rpoB gene for RIF resistance 
mutations consist of:  DNA sequencing (Kapur et al, 1994), heteroduplex analysis 
(William et al, 1998), polymerase chain reaction-single strand conformation 
polymorphism (Telenti et al, 1993, Heym et al, 1994), dideoxy fingerprinting (Femlee et 
al, 1995), line probe assay (Cooksey et al, 1997, Goyal et al, 1997, Hirano et al, 1999, 
Srivastava et al, 2004), molecular beacon (Piatek et al, 1998, El-Hajj et al, 2001), 
mismatch analysis (Nash et al, 1997), real-time PCR (Garcia de Viedma et al, 2002, 
Torres et al, 2003), high density probes assays (Troesch et al, 1999, Sougakouff et al, 
2004, Wada et al, 2004) and micro arrays (Yue et al, 2004).  
 
2.7.2.1. DNA SEQUENCING 
 
DNA sequencing is the most accurate and reliable method for detection of mutations. It is 
used as the gold standard for detection of mutations which are believed to be predictive of 
resistance (Kapur et al, 1994). The added advantage of this method is that it has been 
automated, which has simplified the process. Accurate sequence data can be obtained 
within 48 hours from automated analyzers that use fluorescent chemistry methods. 
Except for RIF, DNA sequencing is unlikely to be used in the routine detection of drug 
resistance mutations because it requires several sequencing reactions per isolate which 
makes it labour-intensive and expensive. However, this method is impractical for use in 
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routine detection of drug resistant mutations because it requires specialised equipment 
and is labour-intensive and expensive.  
 
2.7.2.2. HETERODUPLEX ANALYSIS 
 
Heteroduplex analysis is a method of detecting gene mutations by mixing PCR- amplified 
mutants followed by denaturation and reannealing (Williams et al, 1998; Bahrmand et al, 
2000). The resultant products are resolved by gel electrophoresis. When two single strand 
DNA molecules differing in their base matching form a heteroduplex, the resultant 
conformation is altered, accompanied by a reduced electrophoretic mobility compared to 




Dideoxyfingerprinting (ddF) involves dideoxy sequencing followed by non-denaturing 
electrophoresis and was first described by Sarkar et al, in 1992. “Fingerprint” or 
bandshifts where changes in sequences are present is observed in mutated DNA 
sequences. The theoretical basis for identification of DNA sequence changes is twofold: 
(i) secondary structural differences of single-strand DNA (full length and strand 
termination) and (ii) alterations of the termination site of the primer extension product. 
The time required for detection of RIF-susceptibility using this method was reduced to 2 
days (Femlee et al, 1995). They compared this method to SSCP and found that the 
increased molecular complexity inherent in ddF increases the efficiency of detecting and 
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discriminating base changes. This same increased complexity contributed to the 
observation that ddF analysis was less influenced by the location of the mutation, size of 
the DNA fragment being investigated, temperature and other experimental conditions. 
These attributes of ddF allowed for greater accuracy in the identification and 
characterisation of mutations in a reference laboratory setting.  This method is not 
favoured since the use of radioactivity is involved and thus is costly in terms of waste 
disposal. 
 
2.7.2.4. DENATURING GRADIENT GEL ELECTROPHORESIS 
 
Denaturing gradient gel electrophoresis (DGGE) is a molecular technique that 
distinguishes mutant amplicons from their wildtype equivalents. This method is more 
sensitive when compared to DNA sequencing as it can detect point mutations and small 
insertions and deletions. The principle of this technique is that the melting temperature of 
DNA changes as its fragments migrate through a gradient of denaturants (McCammon et 
al, 2005). A molecular fingerprint is generated based on the characteristic denaturation 
pattern of different mutational variants within a DNA fragment. Scarpellini et al, (1999) 
successfully applied this technique in the detection of mutations associated with RIF 
resistance within the rpoB gene.  
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2.7.2.5. LINE PROBE ASSAY 
 
By examining the sequence data in sensitive and resistant strains, probes can be designed 
and immobilised onto a membrane. Detection of susceptibility or resistance can be done 
by a reverse hybridisation principle (Saiki et al, 1989). PCR is performed on the region of 
DNA in which mutations are associated with drug resistance. The PCR product is then 
allowed to hybridize with the probes on a membrane. Failure to bind the wild type probe 
is due to the presence of a mutation and thus is predictive of drug resistance. The 
commercially available line probe assay for detection of mutations in the rpoB core 
region (De Beenhouwer et al, 1995; Cooksey et al, 1997; Bartfai et al, 2001) is based on 
this principle. The region is amplified and biotin labelled by PCR. The DNA is detected 
after hybridisation with a strip in which 5 probes for wild type rpoB sequences, 4 for 
specific rpoB mutations, a conjugate control and M. tuberculosis control probes are 
immobilised. The bound DNA is detected with a colour reaction.  
 
The advantage of this method is that it can detect mutations directly from clinical 
specimens. However, its limitations are that it is costly and also detects only four 
mutations. Oliveira et al (2002) reported an overall accuracy of 97.6% for detection of 
susceptibility by this assay when compared to conventional resistance testing. These 
results were concordant with those of Rossau et al (1997). The price of this test limits its 




2.7.2.6. RNA/RNA MISMATCH ANALYSIS 
 
RNA/RNA mismatch analysis is based on the ability of double stranded RNA to 
withstand digestion with RNAse A (Nash et al, 1997). Target DNA is amplified by using 
primers which incorporate T7 RNA polymerase and SP6 RNA polymerase promoters in 
opposite directions, allowing RNA to be transcribed by using the PCR product as a 
template. A RIF sensitive strain is also amplified by using the same primers but with the 
SP 6 and T7 promoters incorporated in the strands complimentary to the test strain. The 
test PCR product and the reference PCR product are combined in a transcription reaction 
using either T7 or SP6 RNA polymerase. The complimentary transcripts from the test and 
PCR products are allowed to hybridise and the resulting hybrids are treated with RNAse. 
Any mutations in the test transcript will not pair with the reference transcript and so the 
hybrid will be cleaved at that point. Undigested transcripts and cleavage products can be 
detected using agarose gel electrophoresis. 
 
2.7.2.7. REAL TIME PCR 
 
Real time PCR combines both rapid-cycle PCR and real time monitoring of the 
processing and generation of mutation profiles. Mutations can be monitored using 
fluorescent probe melting profiles. This method is very expensive and also requires 
sophisticated equipment. However, real-time based PCR has been shown to be highly 
specific and sensitive in detection of drug resistant M. tuberculosis. This has been applied 
directly on sputum samples from TB patients, giving results within 3 hours from DNA 
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preparation. In 2000, Torres et al described real-time PCR for the detection of resistance 
associated mutations in M. tuberculosis using fluorescence. 
 
Methods based on real-time PCR have utilised fluorescence resonance energy (FRET) 
probes (Torres et al, 2000; Garcia de Viedma et al, 2002), molecular beacons (El-Hajj et 
al, 2001; Piatek et al, 1998; Piatek et al, 2000) and Taqman Minor Groove Binding 
(MGB) probes (van Doorn et al, 2003). Wada et al (2004) investigated a real time PCR 
based system with Taqman MGB probes to detect mutations associated with resistance of 
M. tuberculosis to INH, RIF and EMB. Taqman MGB probes can distinguish single base 
mismatches.  The specificity of MGB probes was shown to be quite high (Kutyavin et al, 
2000). Drug resistant M. tuberculosis can be detected by changes in the cycle threshold 
values (∆Ct) with Taqman MGB probes in real-time PCR (Kutyavin et al, 2000). The 
shortcoming of this method is its inability to define the exact nucleotide substitution 
involved in the mutation. However, results can be obtained in 30 min. 
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2.7.2.8. SINGLE-STRAND CONFORMATION POLYMORPHISM 
 
Single-strand conformation polymorphism (SSCP) analysis is used to identify genetic 
locations encoding mutations without the need for DNA sequencing of the entire gene. 
The basis of this technique is that electrophoretic mobility of DNA in a non denaturing 
gel is sensitive to both size and shape. Based on intra-molecular interactions and base 
stacking, single stranded DNA can adopt a conformation which is dependent on sequence 
composition. When even a single base is changed the conformation is affected, thus 
changes can be detected as alterations in the electrophoretic mobility of the single-
stranded DNA in non denaturing polyacrylamide gel (Telenti et al, 1993a). Although this 
technique is cost-effective, simple and sensitive, it has its drawbacks in that it may lead to 
false positive results due to silent mutations (Kim et al, 1997). In addition, it has a high-
risk of contamination due to extensive post-PCR manipulation required. 
 
2.7.2.9. MOLECULAR BEACONS 
 
Molecular beacons are hairpin-shaped probes able to detect the presence of specific 
nucleic acids (Piatek et al, 2000). In this assay, the loop portion of the molecule is 
designed to complement the target nucleic acid molecule. Complementary arm sequences 
at the ends of probe sequence can anneal to form a stem. The end of one arm of the 
molecule has a quenching moiety attached to it whilst the other end has a fluorescent 
moiety attached to it. Fluorescence of the fluorophore is reduced by transfer of energy 
which results from close proximity of the two moieties to each other. A longer and more 
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stable hybrid than the stem hybrid is formed when the probe encounters a target 
molecule. 
 
Fluorescence can be detected when the molecular beacon undergoes a spontaneous 
conformational reorganisation that forces the stem apart. This causes the fluorophore and 
the quencher to move away from each other restoring fluorescence. This is monitored in 
real-time, where the fluorescence increases with every cycle in proportion to the 
amplification of the hybridising target, which is not detected in cases when the target is 
not complementary to the beacon (Marras et al, 1999). Beacon assays are performed in 
sealed wells thus preventing contamination. They are easily implemented, automated and 
can be used in high throughput analyses. In the case of RIF, a set of 5 beacons has been 
designed to cover the rpoB core region in a single reaction with excellent results (El-Hajj 
et al, 2001). The results for RIF resistance were obtained directly from sputum specimens 
in less than 3 hrs. The assay is sensitive enough to detect 2 bacilli, with results available 
within 3 hours from sputum collection.  
 
Piatek et al (2000) designed a set of beacons to screen for mutations in the regions 
associated with drug resistance for INH [katG gene (position 315), the promoter region of 
inhA, the oxyR-ahpC intergenic region and position 66, 269, 312, and 413 of kasA]. The 
beacons are highly sensitive and specific: a single mismatch in the target sequence 
diminishes the beacon-target hybrid stability, allowing the detection of point mutations.  
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2.7.2.10. DNA MICROARRAYS 
 
DNA microarrays are based on the principle of hybridisation (Brown et al, 2006). They 
allow analysis of large numbers of DNA sequences in a single hybridisation step. PCR 
amplicons labelled with fluorophore moieties are generated from the sample to be 
hybridised to a large collection of probes bound to a solid surface. The bound amplicons 
emit fluorescent signals that are scanned with an epifluorescent microscope. Probes are 
designed to hybridise to fully complementary amplicons. Wildtype and mutant probes are 
included in the array to determine the presence of specific mutations. Microarrays have 
been used mainly for species identification and for detection of mutations associated with 
RIF-resistance, with excellent concordance with sequencing results (Gingeras et al, 1998; 
Troesch et al, 1999).  
 
In 2004, Sougakoff and others detected rpoB mutations associated with RIF-resistance 
using a high density probe array. DNA microarray systems are composed of 
oligonucleotides synthesized onto a silica slide. Thousands of specific DNA or RNA 
sequences can be detected simultaneously using this system. Yue et al (2004) developed 
an in-house oligonucleotide based microarray for detection of M. tuberculosis resistant to 
RIF in clinical isolates. They reported this assay to be inexpensive, flexible and easy to 
perform when compared to high density DNA probe. The widespread application of 
microarrays is limited to the research setting because they require expertise, sophisticated 
equipment and are costly.  
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2.7.2.11. AMPLIFICATION REFRACTORY MUTATION SYSTEM 
  
The amplification refractory mutation system (ARMS) was first introduced for the 
detection of any point mutations by Newton et al, in 1989. Fan et al, 2004 modified this 
method for the detection of the rpoB gene mutations in M. tuberculosis. It is simple, rapid 
and inexpensive. The principle of ARMS is that oligonucleotides which are 
complimentary to a given DNA sequence except for a mismatch at their 3’-OH residue 
will not function as primers in PCR under appropriate conditions. This is due to the 
absence of the 3’- exonuclease proofreading activity associated with Taq DNA 
polymerase.  
 
In this method, the 3’-end of a wild type PCR primer is located at the mutation site. In the 
case of the wild type template, the DNA polymerase will amplify the DNA efficiently, 
yielding a clear band during gel electrophoresis. In the case of mutant template, the 3’-
end of the primer will not hybridise and the DNA polymerase will not amplify resulting 
in the absence of the band during gel electrophoresis. The major advantages of this 
method are that it is convenient, relatively inexpensive and easy to perform since it 
utilises commonly available reagents and equipment. It can be performed in one day as it 
requires only PCR and electrophoresis of PCR products in an agarose gel. Its sensitivity 
is comparable to the above mentioned molecular assays. 
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2.7.2.12. GeneXpert MTB/RIF assay (Cepheid) 
 
The GeneXpert system is fully automated and intergrates all the steps required for PCR-
based DNA testing. It is designed to purify, concentrate, detect and identify targeted 
nucleic acid sequences directly from unprocessed samples. The system consists of an 
instrument, personal computer, barcode scanner and preloaded software for running tests 
on collected samples and viewing the results. It requires the use of single disposable 
GeneXpert cartridges that hold the PCR reagents and host the PCR process.  
 
The Xpert MTB/RIF includes reagents for the detection of TB and RIF resistance as well. 
A sample processing control ensures adequate processing of the target bacteria and to 
monitors the presence of inhibitor’s in the PCR reaction. The primers in the Xpert 
MTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair “core” 
region. The probes are able to differentiate between the conserved wild-type sequence 
and mutations in the core region that are associated with RIF resistance. 
 
Helb et al, 2010 developed and performed the first analysis of the GeneXpert MTB/RIF 
assay demonstrating a high sensitivity and specificity to both MTB and RIF resistance 
detection.  In this study they reported a detection sensitivity of 71.7% and specificity of 
84.6% of smear negative culture positive clinical samples from Vietnam. In a study of re-
treatment cases in Uganda, the Xpert MTB/RIF detected 98.4% culture positives and 
100% RIF resistance.  Boehme et al, 2010 reported a sensitivity of 98.2% among smear-
positive tuberculosis, 72.5% of smear negative and a specificity of 99.2%. For RIF 
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resistance detection, a sensitivity of 97.6% was reported and a specificity of 98.1%. In 
South Africa, the assay was evaluated in a high HIV prevalence region. A sensitivity and 
specificity of 86% and 95% in HIV negative patients while 85% and 93% for HIV 
positive patients. Also 100% detection in smear positive culture positive and 65% 
detection in smear negative culture positive specimens (Scott, 2010). 
 
Although this technique provides quite a number of advantages such as less hands on 
time on specimen preparation, results are obtained in less than 2 hours and concurrent 
detection of M. tuberculosis and RIF resistance, however it requires sophisticated 
equipment which is expensive for developing countries. Butkus (2010) in his review 
estimated the cost of this system to be $30 000 and the cost per test to be about $64. 
 
2.7.2.13. REVERSE LINE BLOT HYBRIDISATION 
 
The reverse line blot hybridisation method is another molecular method that rapidly 
detects mutations. Morcillo et al, 2002 applied this method for detection of rpoB 
mutations hence it was called rifampicin oligonucleotide typing (rifoligotyping in short). 
A combination of DNA amplification by PCR and reverse line blot hybridisation is 
involved in this assay. Specific primers are used to amplify the rpoB gene of M. 
tuberculosis by PCR. PCR products are then hybridised to oligonucleotide probes (Saiki 
et al, 1989). The membrane has oligonucleotide probes encoding consecutive parts of the 
rpoB gene sequence with the most frequently occurring mutations in RIF resistant strains 
(Morcillo et al, 2002).  
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The rpoB PCR products of the RIF resistant strains will fail to hybridise to one or more 
of the wild type oligonucleotides and will in most cases show affinity to mutant 
oligonucleotides (Kremer et al, 2002; Morcillo et al, 2002). Resistance is detected within 
a few hours and 43 samples can be tested at once. Application of these methods directly 
to clinical specimens will greatly decrease the detection time for rifampicin resistance 








Timely detection M. tuberculosis is important because of the need to make decisions 
regarding management such as commencement of anti-tuberculosis drug therapy, 
isolation precautions, and prophylaxis. Delayed diagnosis due to delays in identification 
of the M. tuberculosis complex was one of the problems identified during investigations 
of outbreaks of MDR TB (CDC, 1993). Although a presumptive diagnosis of pulmonary 
tuberculosis can be made on the basis of patient history, clinical and radiological 
findings, the definitive bacteriological diagnosis of TB continues to depend on the 
microscopic examination of acid fast stained sputum smears followed by culture 
confirmation (Kocagöz et al, 1993). Direct microscopy by Ziehl-Neelsen staining to 
identify acid-fast bacilli (AFB) is the most rapid method (24hrs) but it lacks sensitivity 
and specificity.  
 
The Center for Disease Control and Prevention (CDC) recommended the use of both 
liquid and solid media for mycobacterial culture and a rapid method for identification of 
M tuberculosis complex. These results should be obtained within 21 days of specimen 
receipt in the laboratory. Although this achievement represented a marked improvement 
in the laboratory turnaround time, a delay of 21 days for a definitive diagnosis of TB was 
still not optimal. Thus, the Polymerase Chain Reaction (PCR) assay was developed in 
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response to the need for a more reliable, rapid diagnostic test targeting unique or specific 
sequences in M. tuberculosis (Brisson-Noël et al, 1989; Thierry et al, 1990; Eisenach et 
al, 1991; Cousins et al, 1992) 
 
The efficiency of the PCR assays in clinical specimens is dependent on both the target 
sequence selected and on the efficiency of the DNA extraction procedure (Aldous et al, 
2005). However, the major disadvantage of PCR is the presence of inhibitors in clinical 
specimens, which interferes with amplification-based techniques (Nolte et al, 1993). This 
may result in up to 20% false negatives (Clarridge et al, 1993; Nolte et al, 1993). 
Insertion sequence IS6110 is the commonest target for PCR based detection of M. 
tuberculosis (Thierry et al, 1990). This insertion sequence is reported to be present in 
multiple copies in M. tuberculosis chromosomes and to be specific for M. tuberculosis 
complex. The repetitive nature of this target sequence amplified by PCR contributes to 
the high sensitivity. Therefore, the test is able to theoretically detect a single M. 
tuberculosis organism and its sensitivity is close to 100% in clinical isolates (Eisenach et 
al, 1990).  
 
The isolation of amplifiable DNA template from clinical material is a crucial step in the 
direct detection of M. tuberculosis by PCR. However, there are several difficulties 
associated with PCR. The tough and complex cell wall complicates purification of DNA 
in comparison to that of bacteria with relatively fragile walls (Brennan and Naikado, 
1995). The mycobacteria have cell walls with copious amounts of polysaccharides, which 
can adversely influence subsequent manipulation of DNA. Endogenous inhibitors such as 
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tissues and cell constituents present in sputum as well as inhibitors introduced by reagents 
during DNA isolation have been reported to occur in 32-52 % of respiratory samples 
(Forbes and Hicks, 1996; Kearns et al, 1998). 
 
Numerous protocols have been proposed for DNA extraction of mycobacteria for PCR, 
most of which have included use of detergents, proteolytic enzymes and/or organic 
solvents (Boom et al, 1990; Perera et al, 1994; Noordhoek et al, 1995; Singh et al, 2000). 
Chakravorty and Tyagi (2001) showed that the introduction of a cleaning step before lysis 
results in effective removal of biological constituents and potential PCR inhibitors 
present in the specimen. This creates a better environment for efficient lysis of 
mycobacteria rendering further purification of DNA unnecessary. In this study, four DNA 
extraction techniques: the Chelex based extraction method, IDI lysis kit, Qiagen 
extraction kit and silica based extraction method were evaluated to determine the one that 





3.2. MATERIALS AND METHODS 
 
3.2.1. PATIENT RECRUITMENT AND SPECIMEN COLLECTION 
 
Informed consent was obtained from patients with respiratory disease other than TB, 
attending the respiratory clinic at Inkosi Albert Luthuli Central Hospital (IALCH). 
Patients were requested to expectorate large volumes of phlegm in a container over a 1 
hour period. Sputa were collected and processed at the department of Medical 
Microbiology laboratory at the Nelson R Mandela School of Medicine.  
 
3.2.2. PROCESSING OF SPUTUM SPECIMEN 
 
3.2.2.1. LIQUEFACTION OF SPECIMENS 
 
The external surface of the container was wiped with phenol disinfectant. The sputum 
specimen was transferred into a 50ml tube using a sterile wooden stick. The amount of 
sputum in the tube was estimated and an equal volume of N- acetyl-L-cysteine (NALC) 
was added to the sputum. The cap was tightened firmly and tube vortexed until the 
specimen was liquefied (~15 min). For excessively mucoid sputa, extra NALC was 
added. Approximately 90% of the liquefied sample was aliquotted into 1ml amounts in 
1.5 ml eppendorf tubes. The rest was decontaminated as in 3.2.2.2. The processing of the 
sputum specimens was carried out in a Biological Safety Cabinet (BSC) in a biosafety 
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level 2 (BSL2) laboratory and ensuring minimal aerosol generation to prevent cross 
contamination. 
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3.2.2.2. DECONTAMINATION OF SPECIMENS 
  
Approximately 1ml of the liquefied sputum was added to 0.5ml of 4% NaOH, the 
mixture was vortexed and allowed to stand for 15 min (not more than 20 min). Phosphate 
buffer was added to the 50ml mark of the polypropylene tube. This was followed by 
centrifugation at 3000g for 20 min after which the supernatant was decanted into 
concentrated phenol disinfectant carefully to minimize aerosol generation. The pellet was 
resuspended in 1ml of phosphate buffer and mixed well by vortexing. E. coli and 
decontamination reagents were simulateneously processed to serve as negative controls 
and to control for contamination respectively. Contamination was also controlled by use 
of a single Pasteur pipettes per sample and the processing of small batches at a time.  
 
3.2.2.3. SMEAR MICROSCOPY 
 
One drop, equivalent to 100 µl of decontaminated suspension, was dispensed into a slide 
which was irradiated under UV light on a hot plate for a minimum of 30 minutes. This 
was followed by Ziehl Nielsen staining of the slides. Briefly; the slides were flooded with 
0.3% Carbol Fuchsin. The slides were then flamed using a rod with cotton wool dipped in 
70% alcohol for 5 minutes. The process was repeated three times after which the slides 
were rinsed with water and decolorized with 3% acid alcohol for 2 minutes. This was 
followed by counter staining with methylene blue for 2 minutes. The slides were rinsed 
with tap water and allowed to air dry. Examination for acid fast bacilli that appeared red 
was done under oil immersion at 100 x. Quality control slides were performed using M. 
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tuberculosis H37Rv as a positive control and E. coli as a negative control and these 




A sterile Pasteur pipette was used to inoculate 500 µl of decontaminated deposit into MB 
broth and incubated aerobically at 37ºC for 5 days. This was used to inoculate 
Lowenstein-Jensen (LJ) slants, which were rotated to ensure even distribution of the 
inoculum. Slants were incubated at 37ºC aerobically for 3 weeks. 
 
3.2.2.5. IS6110 PCR 
 
The remaining 400µl suspension was centrifuged at 12 000 g for 15 min. The supernatant 
was discarded and pellet resuspended in 200µl of 1 x TE buffer. This was stored at -4ºC 
until required.  DNA was extracted by the Qiagen method. A 123 bp sequence within the 
IS6110 insertion sequence element was amplified by PCR to determine whether the 
sputum specimens were negative or positive for TB. Amplification was carried out in a 
thermal cycler (Gene Amp PCR System 9700) in a total reaction volume of 50 µl.   
 
The PCR reaction mixture contained 10.0 µl of template DNA, 50 mg/ml of T4 primer, 
50 mg/ml of T5 primer, 1.0 µl of 25 mM deoxynucleoside triphosphates (dNTP’s), 0.5 µl 
(5 U/µl) of Taq DNA polymerase, 5.5 µl of PE buffer, 1.5 µl of 25 mM MgCl2, 3.73 µl of 
BSA and 27.6 µl of nuclease free water. The reaction mixture was incubated at 94°C for 
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2 min to denature the DNA. This was followed by 35 cycles of amplification, each of 
which consisted of three steps in the following order:  denaturation at 94°C for 45 sec, 
annealing at 68°C for 45 sec and extension of the primers at 72°C for 2 min.  Final 
extension was conducted at 72°C for 5 min. Amplification products were electrophoresed 
in a 1.5 % Agarose gel containing ethidium bromide, at 100 V for 60 min. They were 
then visualized using a UV transilluminator. The same PCR was used to identify the 
DNA extraction method that was optimal for removal of inhibitors in PCR as well as to 
determine the sensitivity of detection. Different rooms were used for DNA extraction, 
preparation of reagents for PCR, addition of DNA to the mastermix reagents and PCR 
amplification; to reduce the risk of cross-contamination of DNA. The risk of 
contamination was also reduced by the use of plugged pipette tips and liberal use of 5% 
hypochlorite. 
 
3.2.2.6. STORAGE OF SPUTUM SPECIMENS 
 
Sputum specimens were stored at 4ºC until PCR results were available. These results 
were then compared to the smear results and if both were negative, the sputa was pooled 
and used in the spiking experiments. 
 
3.2.3. PREPARATION OF INOCULUM 
 
M. tuberculosis was grown to mid log phase on Lowenstein-Jensen slopes until confluent. 
A wooden stick was used to transfer a loopful of culture into a tube containing phosphate 
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buffer, 0.05% Tween 20 and 5-10 glass beads (3 mm). The tube was vortexed for 5 min 
to break down clumps which were allowed to settle for 45 min. Thereafter, the upper part 
of the bacterial suspension (3 ml) was transferred to a sterile tube. The bacterial 
suspension was aspirated ten times with a syringe and a 26 inch gauge needle. The cell 
suspension was then passed through a 5 µm filter. The turbidity of the bacterial 
suspension was adjusted to a McFarland standard number 1 (~ 107 CFU/ml) with 
phosphate buffer containing 0.05 % Tween 20. This adjusted bacterial suspension was 
used to spike TB negative sputum. 
 
3.2.4. SPIKING OF NEGATIVE SPUTUM WITH STANDARDIZED M. 
tuberculosis  
 
A 10-fold serial dilution was prepared by aliquoting 3.6 ml of the pooled, liquefied TB-
negative sputum into eight 10 ml tubes. Four hundred µl of the standardised bacterial 
suspension was added to the first tube. This was thoroughly vortexed, following which 
400µl of the spiked sputum was transferred to the next tube. This process was repeated 
until the last tube. From each dilution, 500µl each was aliquoted into four 2 ml eppendorf 
tubes, which were stored at 4ºC for evaluation of the four DNA extraction methods. The 
remaining aliqout in each dilution was decontaminated using 4% NaOH as mentioned in 
3.2.2.2 and 20µl were plated out in triplicate on a Middlebrook 7H11 agar plates. These 
plates were then sealed in CO2-permeable plastic bags and incubated aerobically for 3 
weeks at 37°C. Thereafter, colony counts were performed and the initial bacterial density 
was calculated using the following formula: 
 56 
Bacterial density (CFU/ml) = 50 x Colony count x Dilution factor  
 
3.3. DNA EXTRACTION 
 
Four DNA extraction methods, the Chelex based extraction method, the IDI lysis kit, the 
Qiagen extraction kit and the silica based extraction method, were used to extract DNA 
from liquefied, spiked sputum specimens to determine which was most effective in 
removing inhibitors of PCR in the sputum. Water was simultaneously processed with the 
spiked sputum specimens to serve as a negative control and also to control for 
contamination. The resultant DNA was amplified by the IS6110 PCR to confirm the 
absence of inhibitors and to determine the least number of organisms that can be detected. 
 
3.3.1. CHELEX EXTRACTION METHOD (Chakravorty and Tyagi, 2001) 
 
An aliquot of liquefied, spiked sputum specimen was heat killed for 15 min at 100°C. An 
equal volume (500 µl) of inhibitor removal solution (IRS) (Appendix I) was added. The 
mixture was vortexed, incubated for 10 min at 37°C and then centrifuged at 12 000 g for 
10 min. The supernatant was discarded and the pellet was washed with 1 ml sterile water. 
Five volumes of DNA extraction solution (50 µl) (Appendix I) was added, followed by 
incubation at 95°C for 15 min. The cell debris was pelleted by centrifugation for 10 min 




3.3.2. SILICA BASED METHOD (Boom et al, 1989) 
 
An aliquot of 500 µl liquefied, spiked sputum specimen was heat killed for 15 min at 
100°C. One milliliter (ml) of lysis buffer (Appendix I) and 40 µl of acid washed silica 
(Appendix I) respectively, were added to the tubes. These were incubated for 15 min at 
room temperature with constant mixing. This was followed by centrifugation at 12 000 g 
for 30 s and the supernatant was discarded. The pellet was washed twice with 1ml wash 
buffer (Appendix I) at room temperature, centrifuged for 30 s and supernatant discarded. 
This was followed by two washes with 1ml and 500µl respectively of 70% ethanol. After 
centrifugation at 12 000 g, the supernatant was discarded. This was followed by one wash 
with 1ml acetone and centrifugation at 12 000 g for 30 s. After the supernatant was 
discarded, the pellet was dried in the biosafety cabinet (BSC) with Eppendorf tube caps 
left open. Thereafter, 75 µl of 10mM Tris-HCl and 1 mM EDTA (1 x TE buffer), ph 8.0 
was added. The tubes were vortexed briefly and then incubated at 55ºC for 10 min to 
elute the DNA. They were then centrifuged at 12 000 g for 2 min. The supernatant was 
transferred to a new tube and stored at -20°C for further use. 
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3.3.3. IDI EXTRACTION (Infectio Diagnostic, Inc., Quebec, Canada) 
 
DNA was extracted from an aliquot of liquefied, spiked sputum specimen according to 
the manufacturer’s instructions. Briefly, 500µl of the spiked sputum specimen was 
transferred to a lysis tube which was vigorously mixed for 5 min in a Vortex Genie 2. 
The mixture was centrifuged at 1000g for 5 min followed by heating at 95°C for 2 min. 
The supernatant was discarded using a pipette. The pellet was washed twice in 100µl of 
sample buffer and centrifuged at 14 000 g for 5 min. It was resuspended in TE buffer. 
The lysis tube was immediately placed on ice and then stored at -20°C for further use. 
 
3.3.4. QIAGEN QIAamp DNA EXTRACTION (QIAGEN, Valencia, CA)  
 
An aliquot of liquefied, spiked sputum specimen was heat killed for 15 min at 100°C. To 
this, 180 µl of lysozyme (30 mg/ml) dissolved in tissue lysis buffer was added and 
incubated for at least 30 min at 37°C. Following this, 20µl Proteinase K (20 mg/ml) and 
200µl buffer AL were added. The tubes were mixed by vortexing and then incubated first 
at 56°C for 30 min, followed by 95°C for 15 min. The microcentrifuge tube was then 
briefly centrifuged in order to collect drops from the inside of the lid.  This was followed 
by the addition of 400 µl of ethanol (96-100%), and pulse-vortexing for 15 sec. The 
microcentrifuge tube was briefly centrifuged and the mixture was added to the QIAamp 
spin column (in a 2 ml collection tube) without wetting the rim. The columns were 
centrifuged at 6000 x g for 1 min in a 2 ml tube to collect the filtrate, which was 
discarded.  The column content was washed twice with buffer AW1 and AW2 
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respectively.  To elute the DNA, the column was incubated at room temperature for 1 min 
in 100 µl of Buffer AE followed by centrifugation at 8000 x g for 1 min. The DNA was 
stored at -20°C for further use. 
 
3.4. DATA ANALYSIS 
 
Samples were considered positive for M. tuberculosis if a single band of 123 bp was 
present after gel electrophoresis and no similar bands were seen for the negative control. 
The sensitivity and specificity of the four DNA extraction methods was determined by 
comparing the PCR with culture results as the “gold standard”. The detection limit for 
visualization was determined using the spiked 10-fold serial dilutions of H37Rv M. 
tuberculosis strains in liquefied sputum specimens. The cost effectiveness of each DNA 
extraction method was evaluated by calculating the cost per sample, the time it took to 




3.5.1. SMEAR, CULTURE AND PCR FOR SPUTUM SPECIMENS 
 
A total of 43 sputum specimens were collected from IALCH. For all 43 specimens, no 
AFB was detected under light microscopy.  PCR results showed faint bands for 8 
specimens which were later determined to be false positives as the culture and smear 
results were both negative. One specimen was smear negative but positive by PCR and 
culture. All the sputum specimens that showed faint bands by PCR but were culture 
negative were not pooled since they were old when the culture results became available. 
All the sputum specimens that were negative by PCR and smear were pooled and used for 
spiking experiments. 
 
3.5.2. PCR OF SAMPLES USING THE 4 DNA EXTRACTION METHODS 
 
The experiments were repeated three times. The PCR endpoint was at a dilution of 100 
when Chelex extracted DNA was used (Figure 3.1), while for the silica based extraction 
method, it was at 10-1 (Figure 3.2).  Extractions using the IDI Lysis kit and the Qiagen 
DNA extraction kit produced higher endpoints of 104 and 103 respectively (Figure 3.3 
and 3.4) suggesting the presence of inhibition.  No amplification was observed for the 








Figure 3.1 IS6110 amplification of DNA extracted from serial dilutions of M. 
tuberculosis H37Rv using the Chelex extraction method. Lanes 1 to 9 contain 107 ranging 
down to 10-1 organism/ml. Lane 10 contains pooled and unspiked sputum. Lanes 11 and 
12 contain the negative and positive controls respectively while molecular weight marker 
XIV is in lane 13. 
 
 









Figure 3.2 IS6110 amplification of DNA extracted from serial dilutions of M. 
tuberculosis H37Rv using the silica based extraction method. Lanes 1 to 9 contain 107 
ranging down to 10-1 organism/ml. Lane 10 contains pooled and unspiked sputum. Lanes 
11 and 12 contain the negative and positive controls respectively while molecular weight 
marker XIV is in lane 13. 
 
 









Figure 3.3 IS6110 amplification of DNA extracted from serial dilutions of M. 
tuberculosis H37Rv using the IDI Lysis Kit extraction method. Lanes 1 to 9 contain 107 
ranging down to 10-1 organism/ml. Lane 10 contains pooled and unspiked sputum. Lanes 
11 and 12 contain the negative and positive controls respectively while molecular weight 











Figure 3.4 IS6110 amplification of DNA extracted from serial dilutions of M. 
tuberculosis H37Rv using the Qiagen extraction kit. Lanes 1 to 9 contain 107 ranging 
down to 10-1 organism/ml. Lane 10 contains pooled and unspiked sputum. Lanes 11 and 
12 contain the negative and positive controls respectively while molecular weight marker 








Table 3.1 Colony counts of spiked sputum dilutions and corresponding estimated 
bacterial density 
 

















107 100 ND - * - * - 
106 10-1 * - * - * - 
105 10-2 * - * - * - 
104 10-3 96 0.48 x 104  233 1.17 x 104 238 1.2 x 104 
103 10-4 16 0.8 x 103 33 1.65 x 103 26 1.3 x 103 
102 10-5 3 0.15 x 102 3 0.15 x 102 7 0.35 x 102 
101 10-6 0 0 0 0 2 10 x 101 
100 10-7 0 0 0 0 0 0 
10-1 10-8 0 0 0 0 0 0 
- PU  ND 0 0 0 0 0 
ND = Not done, * = the plates were to dense too count, conc# = concentration, PU = 
Pooled and unspiked 
 
Culture is considered the gold standard for the diagnosis of infections with M. 
tuberculosis. Therefore, the PCR results of the serial dilutions were compared with 
colony counts of the corresponding dilution. For the lower dilutions (107, 106 and 105) the 
number of colonies could not be counted as plates showed dense growth of M. 
tuberculosis H37Rv strain (Table 3.1). There were no colonies present in the highest 
dilutions i.e. 101, 100 and 10-1 for replicate 1 and replicate 2 while for replicate 3 colonies 
were counted at 101. Only dilutions 104, 103 and 102 for all 3 replicates and dilution 101 in 
replicate 3 showed colonies that could be counted. Therefore, the PCR was expected to 
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produce bands until dilution 101 for replicate 3 of DNA extraction methods. However 
both the Chelex and the Silica extraction methods showed bands beyond this dilution. 
 
Table 3.2 Cost-effectiveness of the 4 DNA extraction methods 
 
Extraction method Time (min) Stability of solutions Cost per sample 
Chelex 90 2 months in dark R0.45 
IDI 45 1 year R60.00 
Qiagen 180 1 year R25.36 
Silica 60 3 weeks in dark R2.28 
 
The cost effectiveness of the DNA extraction protocols was evaluated by considering the 
time and effort required during the procedure, the shelf life of the solutions and the cost 




DNA amplification by PCR is a rapid and sensitive method for detection of M. 
tuberculosis in sputum specimens. The methods currently used for isolation of 
mycobacterial DNA from clinical samples suffer from one or more drawbacks that 
include long processing times, use of organic solvents and enzymes and multiple steps 
resulting in either DNA loss or in the inefficient removal of PCR inhibitors (Chakravorty 
and Tyagi, 2001). Multistep methods increase false positive results due to the risk of 
cross-contamination and also false negative reporting due to losses in DNA recovery. 
 
Hashimoto et al (1995) reported a decreased sensitivity in the detection of M. 
tuberculosis by PCR in sputum specimens compared to clinical isolates. They suggested 
that this was due to loss of the DNA during isolation and contamination with inhibitors 
such as phenol during the extraction and purification steps. Incompleteness of the 
bacterial lysis during sample processing has also been reported to significantly lower the 
sensitivity of PCR methods (Bahador et al, 2004). Guanidinium thiocynate (GITC) has 
been reported to effectively remove inhibiting substances in clinical samples (Boom et al, 
1990; Chakravorty and Tyagi, 2001). Similarly, in this study good results were obtained 
with the Chelex and Silica extraction method both of which use GITC.  
 
Chakravorty and Tyagi (2001) suggested that introduction of a “cleaning-before-lysis” 
step resulted in effective removal of biological constituents and potential PCR inhibitors 
present in the specimen. The remaining inhibitors, if present at all, are adsorbed by 
Chelex-100 resin during the DNA isolation step.  
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In this study, the silica extracted DNA was amplified in samples where culture results 
were negative. We suggest that this could have been due to cross contamination and also 
that the PCR is more sensitive than culture.  It has been suggested that substances such as 
alpha casein and bovine serum albumin (BSA), can enhance Taq polymerase activity, and 
thus should be evaluated (Amicosante et al, 1995).  In future studies, these will improve 
PCR yield in sputum samples after processing with GITC or other DNA extraction 
protocols. 
 
The labour required to extract DNA differs from one method to the other. Multistep 
methods increase false positive results due to the risk of cross-contamination and also 
augment false negative reporting due to losses in DNA recovery. These drawbacks have 
been overcome in the IRS method. The Chelex extraction method was found to be the 
least expensive compared to the other methods evaluated in this study and was the most 
efficient in performing DNA extraction for M. tuberculosis PCR with less hands on time.   
 
The IDI and Qiagen extraction methods showed significant inhibition of the PCR and the 
cost per sample was also high. Thus, they were excluded as the methods of choice for 
optimal DNA extraction methods. The Chelex and Silica showed significantly less 
inhibition of PCR products. Chelex was chosen as the method of choice since it cost 5 
times less than the Silica. Also, although the Silica method took less time than the 
Chelex, the silica was more hands on while the slightly long duration of the Chelex, the 
former was more labour intensive. The longer duration (30 min more) of the Chelex was 
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due incubation and centrifugation times and required less hands on time. Based on these 
reasons, the Chelex extraction method was found to be the most cost effective and 
therefore, the method of choice for the extraction of DNA directly from sputum 
specimens. The boiling method, although very rapid, was not considered an option since 





4. DRUG SUSCEPTIBILITY TESTING AND DETERMINATION OF 
MUTATIONS ASSOCIATED WITH RIF RESISTANCE BY SEQUENCING 




In most developing countries, drug susceptibility testing (DST) involves culture of 
isolates on solid media containing the test drug. Although this method provides definitive 
results, delays of at least 14 days are incurred from the time of primary isolation (Collins 
and Franzblau, 1997). This leads to prolonged infectivity of the patients including those 
with drug resistant M. tuberculosis, particularly MDR-TB, which compromises clinical 
success and the effectiveness of TB control programmes (Iseman, 1993). Rapid DST 
results allow the patient to be treated timeously with appropriate drug regimens. In 
addition, early detection of drug resistance and the use of the most effective drugs for 
treatment are therefore very important for proper management of TB patients (Mathew et 
al, 2000).  
 
Molecular techniques have provided an alternative to the conventional susceptibility 
testing of drug resistance. These techniques exploit the genetic mechanisms involved in 
the acquisition of drug resistance by M. tuberculosis. They also enable detection of drug 
resistance within days or even a few hours. M. tuberculosis becomes drug resistant by the 
accumulation of mutations at chromosomal loci. Plasmids or transposable elements are 
not involved in this process. Mutations within an 81-bp region, codon 507-533, (Figure 
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4.1) of the rpoB gene encoding the B chain of the DNA dependent RNA polymerase, 
confers RIF resistance in approximately 90-95 % of all clinical isolates of M. tuberculosis 
(Telenti et al, 1993). These mutations are absent in susceptible isolates, making this 
region an ideal target for molecular drug susceptibility testing. Since RIF monoresistance 
is rare, it can be used as a marker for MDR-TB (Telenti et al, 1993). Therefore, in this 
study the rpoB gene was sequenced to ascertain the most frequently occurring mutations 
in this gene that confers resistance to RIF in isolates in KZN. The ultimate goal was to 




Figure 4.1 The 81-bp region of the rpoB gene that harbours mutations conferring 




4.2. MATERIALS AND METHODS 
 
4.2.1. SPECIMEN COLLECTION 
 
Sputum specimens were collected from 425 MDR-TB patients with informed consent at 
King George V (KGV) hospital. This sputum was used to compare the two molecular 
methods in predicting drug resistance in M. tuberculosis. They were decontaminated by 
the NALC/NaOH method in a BSC and concentrated by centrifugation. The samples 
were portioned into two. One half of the deposit was subjected to routine 
mycobacteriology at the TB laboratory IALCH and the other half was aliquoted in 500 µl 
ml amounts and stored at -70°C for molecular analysis of drug resistance. Cross 
contamination was controlled for by the processing of small numbers of specimens at a 
time 
 
4.2.2. PHENOTYPIC ANALYSIS OF DRUG RESISTANCE 
 
Indirect susceptibility testing of M. tuberculosis isolates was performed on all smear 
positive specimens using the agar proportion method on Middlebrook (MB) 7H10 agar 
plates containing RIF 1mg/ml, INH 1mg/ml, EMB 5mg/ml, OFX 2mg/ml, STR 2mg/ml 
and KM 0.5mg/ml. The isolates were considered resistant if > 1% of colonies grew on the 
antibiotic containing medium compared with the drug free medium.  
 
4.2.3. EXTRACTION OF DNA FROM CLINICAL ISOLATES 
 
Confluent cultures of M. tuberculosis were harvested for MB 7H11 agar and heat killed at 
80ºC for 30 min. DNA was extracted in a BSC according to CTAB method (van Embden 
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et al, 1993). Briefly, cells were lysed by the addition of lysozyme (10mg/ml) at 37°C for 
1 hour.  This was followed by deproteinization by adding 75 µl of 10% SDS/proteinase K 
solution at 65°C for 10 min. The denatured proteins, cell debris and polysaccharides were 
complexed by 100 µl of 5 M NaCl followed by 100µl CTAB/NaCl solution prewarmed 
to 65°C for 10 min at 65°C. These complexes were extracted by 750 µl of 
chloroform/isoamyl alcohol. After centrifugation at room temperature at 12 000 g for 10 
min, the DNA present in the aqueous supernatant was precipitated by adding 500 µl of 
isopropanol at -20 C overnight. DNA was pelleted by centrifugation for 25 min at room 
temperature. The pellet was washed twice with 1 ml 70 % ethanol, air dried and 
redissolved in appropriate amount of 1 x TE buffer. It was then stored at -20°C until used. 
 
4.2.4. ANALYSIS OF THE rpoB GENE BY SEQUENCING 
 
Sequencing was performed in 2 sites, Netherlands and then in the University of Cape 
Town (UCT) when the Dutch collaborators experienced technical difficulties. Ninety 
nine DNA samples were sent to our collaborators in Netherlands after ethanol 
precipitation to preserve the integrity of the DNA shipping.  Briefly, 30 µl of DNA was 
added to 170 µl of 1 x TE buffer. This was mixed well by tapping and then 20 µl of Na 
Acetate (3M, pH 5.2) and mixed gently. This was followed by adding 700 µl of 100% 
ethanol and mixed well. One hundred and thirty eight of the DNA samples were 
amplified by PCR and sent to the UCT for sequencing.  
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4.2.5. PCR  
 
A 437 bp fragment of the rpoB gene was amplified using the forward primer rpoB for1 
5'- TGG TCC GCT TGC ACG AGG GTC AGA-3' and the reverse primer rpoB-rev1 5'- 
CTC AGG GGT TTC GAT CGG GCA CAT-3' according to van der Zanden et al, 
(2003). Water was used as negative control and to control for contamination. Different 
rooms were used for preparation of reagents for PCR, addition of DNA to the mastermix 
reagents and PCR amplification. Cross contamination was also controlled for by the use 
of plugged pipette tips. The reaction mixture is shown in Table 4.1. Thermal cycling 
conditions are shown in Table 4.2. The PCR products were electrophoresed in 1.5% 
agarose gel for confirmation.  
 
       Table 4.1 Reaction mixture for amplifying the rpoB gene from DNA  
PCR reagent Volume  (µL) 
50 pmol rpoB-for1 primer 6.9 
50 pmol rpoB-rev1primer 5’ biotinylated 6.9 
14.5 mM Tris (pH 9.0) 7.9 
500 mM KCl 5.5 
25mM MgCl2  5.0 
0.2 mM dNTP’s 1.5 
Taq DNA polymerase 0.2 
Water 19.1 
DNA (1:10 dilution) 2 




Table 4.2 Cycling conditions for amplification of the rpoB region for sequencing 
Step Time (min) Temperature (°C) No. of cycles 












Extension 5 72 1 
 
 
The PCR products and primers were then sent to UCT for sequencing, which was done 
using the Big Dye terminator v3.1 cycle kit (Applied Biosytem) and a 3130 Genetic 
Analyser (Applied Biosystem) 
 
4.2.6. ANALYSIS OF SEQUENCE DATA 
 
The sequences were analysed using the basic alignment search tool BLAST against the 
GenBank nucleic acid sequence database. The ChromasPro and BioEdit software were 





4.3.1. DRUG SUSCEPTIBILITY TESTING  
 
Table 4.3 shows the indirect phenotypic susceptibility results of clinical isolates of 
M. tuberculosis n = 271 
No. of isolates Sensitive to: Resistant to: 
110 EOK IRS 
70 ESOK IR 
16 ES IROK 
14 IRESOK - 
10 RESOK I 
9 OK IRES 
8 E IRSOK 
6 REOK IS 
5 IESOK R 
4 ESO IRK 
3 SOK IRE 
2 EO IRSK 
2 O IRESK 
2 K IRESO 
2 ESK IRO 
2 IREOK S 
2 IEOK RS 
1 - IRESOK 
1 S IREOK 
1 RES IOK 
1 SK IREO 
E-Ethambutol; I-Isoniazid; K-Kanamycin; O- Ofloxacin; R- Rifampicin; S-Streptomycin 
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Of the 425 sputum specimens that were collected at KGV hospital only 271 had 
susceptibility results available from conventional testing using the proportion method 
(Table 4.3). Of the 271, 231 (85.2 %) were MDR, i.e. resistant to RIF and INH alone, or 
in addition to any of the other drugs. Of these, 26 (9.6%) were XDR (i.e. resistant to OFX 
and KM in addition). Fourteen (5.1%) were sensitive to all the drugs while one (0.4%) 
was resistant to all the drugs. Only five (1.8 %) were resistant to RIF alone and ten 
(3.7%) were resistant to INH alone. 
 
4.3.2. MUTATIONS IN THE rpoB GENE 
 
DNA sequencing analysis of 236 isolates showed that 187 (79.2%) isolates harboured 
mutations in the 81-bp hot spot region of the rpoB gene (Table 4.2). Two of these 187 
isolates were phenotypically susceptible to RIF. Of the 49 isolates with no mutations, 25 
were resistant to RIF and the rest were susceptible on conventional drug susceptibility 
testing. However, there was a significant association between the presence of the 
mutations and resistance to RIF (p = 0.02).  
 
Mutations were most frequently observed in codons 516, 531 and 533 (Appendix II).  
The nucleotide substitution and the subsequent amino changes together with the 
frequency of the different mutations are shown in Table 4.4. Six single mutations and 5 
double mutations were observed. The most frequent mutation was a TCG 531 TTG 
(58%), followed by 516 GAC to GTC (13.8%), then the double mutation 516 GAC to 
GGC/533 CAG to CCG (10.6% ) and codon 533 CAG to CCG (9.5%) alone.   
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Amino acid change No of isolates  
 
516 GAC→TAC ASP→TYR 1 (0.5%) 
516 GAC→GTC ASP→VAL 26 (13.9%) 
526 CAC→GAC HIS→ASP 6 (3.2%) 
526 CAC→TAC HIS→TYR 3 (1.6%) 
531 TCG→TTG SER→LEU 109 (58%) 
533 CTG→CCG LEU→PRO 18 (9.6%) 
510 CAG→CAT LEU→PRO 
516 GAC→TAC ASP→TYR 
1 (0.5%) 
511 CTG→CCG LEU→PRO 
516 GAC→TCC ASP→SER 
1 (0.5%) 
511 CTG→CCG LEU→PRO 
516 GAC→TAC ASP→TYR 
1 (0.5%) 
516 GAC→GGC ASP→GLY 
533 CTG→CCG LEU→PRO 
21 (11.2%) 
531 TCG→TTG SER→LEU 
537 GGT→GAT GLY→VAL 
1 (0.5%) 
- No mutation - 49* (20.7%) 






More than 96% of RIF resistant isolates of M. tuberculosis isolated in different countries 
present with mutations in the 81-bp region of the rpoB gene (Telenti et al, 1993; 
Williams et al, 1998; Hirano et al, 1999; Scarpellini et al, 1999). Different studies have 
reported specific mutation frequencies and also novel mutations (Bartfai et al, 2001; 
Mani et al, 2001). Telenti et al (1997), reported mutations in the rpoB gene in all RIF 
resistant isolates and in none of the susceptible isolates tested. Similarly, Garcia et al 
(2001), reported mutations in the rpoB region in all clinical isolates that were resistant to 
RIF. In the present study, 10% of the RIF resistant isolates did not possess any mutations 
in the rpoB region, which suggests the presence of mutations outside the 437 bp region or 
another resistance mechanism such as efflux pump (Jiang et al, 2008). The mutations 
found in 2 drug susceptible strains may be silent mutations.  
 
Point mutations in the rpoB gene are associated with RIF resistance and codons 516, 526 
and 531 together are known to be the most mutated codons worldwide (Telenti et al, 
1993; Williams et al, 1998; Hirano et al, 1999; Scarpellini et al, 1999).  We found a total 
of 11 different genetic alterations with mutations in codons 516, 531 and 533 occurring in 
80% of RIF resistant isolates. Schilke et al (1999) reported that the most frequently 
mutated codons among South African isolates were 531 (55%), 526 (20%) and 516 
(13%). They also observed a high number of substitutions at codon 526 in contrast to our 
findings. The frequency of point mutations found in isolates originating from different 
geographic regions of South Africa were found to be comparable to those from other 
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countries, mainly the USA and Northern Europe (Schilke et al, 1999).  This was similar 
to our observations. 
 
Kiepiela et al (1998) evaluated 113 RIF resistant isolates of M. tuberculosis in KZN 
using sequencing, PCR-HDR analysis and line probe assay.  They reported 24 mutations 
affecting 13 codons of the rpoB region. In this study, eleven different types of mutations 
were identified in 188 RIF resistant M. tuberculosis clinical isolates. Contrary to our 
findings, Kiepiela et al, (1998) observed numerous different mutations in the 526 codon 
while only 2 different mutations for this codon were seen in this study. Similarly to our 
findings, codon 516, 531 and 533 were the most frequently mutated. Most of the 
mutations reported by Kiepiela et al (1998) were not observed in the isolates of this 
study.  This may be due to the inability of these strains to survive as a result of fitness 
costs incurred by the mutations (Billington et al, 1999). 
 
The frequency of mutations at codons 516, 526 and 531 within the rpoB gene vary 
significantly depending on the geographic location of RIF resistant M. tuberculosis 
isolates. Kapur et al, 1994, reported the occurrence of 5%, 43% and 31% of RIF resistant 
M. tuberculosis isolates from New York and Texas carrying mutations at codon positions 
516, 526 and 531, respectively. Cooksey et al, 1997 have also reported similar 
frequencies (6%, 43% and 33%) among their isolates.  Among the different mutations 
seen at codon 531, in our study, the change of TCG (Ser) to TTG (Leu) occurred at a 
frequency of 58%. Matsiota-Bernard et al (1998), Pozzi et al (1999) and Mani et al 
(2001) also reported similar high frequencies of this mutation, 59, 56 and 49% 
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respectively. The low frequency (3%) of the CAC to GAC in codon 526 was similar to 
that reported by Mani et al (2001) but significantly lower than the 30% found in Italian 
isolates (Pozzi et al, 1999) and 19% in Greek isolates (Matsiota-Bernard et al, 1998). 
Considering the variety of missense mutations occurring at variable frequency in the core 
region of the rpoB gene, the predominance of the 531(Ser-Leu) mutation suggest a 
selective advantage possibly as a result of compensatory mutations. The nucleotide 
substitution at this position may lead to an optimal inhibitory effect on RIF action 
associated at the same time with minimal loss of function of the RNA polymerase 
(Billington et al, 1999) 
 
Mutations 510CAT, 511CCG, 516 TCC and 516GGC were found in combination with 
other mutations i.e. as double mutation within the rpoB gene and thus the extent to which 
they contributed to the resistance of the isolates could not be determined. Although, 
mutations 516TAC and 533CCG were found in combination with some of the above 
mentioned mutations, they were also detected as single mutations and thus it may be 
assumed that they contributed to the phenotypic RIF resistance of these isolates. Studies 
need to be undertaken in future to determine the MICs of these isolates with double and 
single mutations in order to determine the effect of the added mutation on RIF resistance.  
 
The detection of RIF resistance by molecular techniques fails to correlate with the 
resistant phenotype in about 5-10% of all cases (Telenti et al, 1993). Twenty (9.7%) of 
our strains had no mutation detected in the 81-bp core region of the rpoB gene. In these 
strains, RIF resistance could have resulted from the presence of mutations outside the 
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locus sequenced, novel mechanisms, or heteroresistance. Heep et al, (2000) reported a 
mutation in the beginning of the rpoB gene conferring resistance to RIF in Helicobacter 
pylori (V149F) and subsequently in M. tuberculosis (Heep et al 2001). They showed that 
RIF resistance was associated with the V176F mutation of the rpoB gene when cluster I 
to III mutations were excluded. In their study, it was shown that the mutation V176F 
conferred high-level resistance in clinical M. tuberculosis isolates which could account 
for more than 1% of all RIF resistant strains.  
 
Alternative mechanisms such as cell wall permeability, plasmids or transposons (which 
could carry resistant determinants), and mutations elsewhere in the genome are all 
unlikely, although mutations in other RNA polymerase subunits is a possibility (Heep et 
al, 2000). The inactivation of RIF by ribosylation has been reported in several fast 
growing mycobacterial species, all of which are naturally resistant to RIF but it is not yet 
known whether this activity is also present in M. tuberculosis. Approximately 10% of our 
RIF resistant M. tuberculosis isolates did not show any mutations in the rpoB region. 
This was similar to findings of Yue et al (2003) but much higher than other studies 
(Hirano et al, 1999; Telenti et al, 1993), 4, 5 % respectively. In this study other possible 
mechanisms of drug resistance were not investigated and future studies should be 
undertaken to explore other reported mechanisms of resistance such as the efflux pump 
system, inactivation of ribosylation and mutations in the V176F region in order to 




Kapur et al (1994) reported rare mutant rpoB alleles in isolates from Victoria, Texas. 
These were also observed in one of our strains that had combination of point mutations in 
two non- contiguous codons. Novel mutations not previously published, were 
demonstrated in this study. However, no direct link could be made to RIF resistance as 
they were always associated with other known mutations. Since the frequency of 
mutations in the rpoB of M. tuberculosis can vary according to geographic area, it is 
important to sequence isolates of that region in order to determine the prevalent 
mutations. This will allow utilization of molecular techniques that are better suited for 








The reverse dot blot assay was first described in 1989 by Saiki et al for the detection of 
the HLA-DQA genotype and the Mediterranean β-thalassemia mutations in human DNA. 
This was later modified to develop the reverse line blot assay by Kaufold et al, 1994 for 
the M protein gene of the group A streptococci. In this assay, the membrane bound probe 
was hybridised to the PCR product which was free in solution (Zhang et al, 1991). Prior 
to use, the membrane was prepared by activation with 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDAC) which in turn activated carboxyl groups on the membrane to form 
O-acylurea. These intermediates could be linked by amines to form amide bonds (Figure 
5.1). 
 








The covalent binding of an amino linked oligonucleotide to a negatively charged 
membrane pushed the probe outwards, making it accessible to react with the target DNA 
during hybridisation (Kaufold et al, 1994). After immobilisation of the probes, the 
remaining active carboxyl groups that were reactive to any nucleophile present in 
solution were quenched with NaOH. This prevents non-specific binding through 
electrostatic, hydrophobic or chemical interactions which can reduce the sensitivity of the 
assay without affecting the covalent bonds between oligonucleotide probes and the 
membrane. Since the bound probes could withstand multiple, stringent hybridisation and 
washing conditions, the membrane could be reused many times after being stripped 
(Kamerbreek et al, 1997).  
 
The reverse line blot assay has been used to predict RIF resistance by detecting mutations 
in the rpoB region of the RNA polymerase in M. tuberculosis (Morcillo et al, 2002, van 
der Zanden et al, 2003, Mokrousov et al, 2004, Figure 5.2). Since these mutations are 
associated with resistance to RIF, the assay was termed the Rifampicin oligonucleotide 
typing assay (Rifoligotyping assay) and in turn was abbreviated: RIFO assay (Kremer et 
al, 2002). Multiple genetic loci, as well as a large number of samples could be analysed 
in parallel, with considerable savings of cost, time and effort. This assay would be useful 
as a rapid diagnostic tool for large scale detection of drug resistance in settings with high 
prevalence of MDR/XDR-TB.  
 
In this study, we aimed to optimise this technique for direct detection of RIF mutations in 















Figure 5.2 Diagrammatic representation of RIFO assay. W= wild type; M = 
mutant. The wild type oligonucleotides were derived from the sequence of 
the ‘hot spot’ region of the rpoB gene of a drug susceptible M. 
tuberculosis strain. The mutant oligonucleotides were derived from the 
sequences of the ‘hot spot’ region of the rpoB gene of various drug 
resistant M. tuberculosis strains (Morcillo et al, 2002).  
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5.2. MATERIALS AND METHOD 
 
5.2.1. PATIENT RECRUITMENT 
 
Patients diagnosed with MDR TB were recruited at KGV Hospital during the period of 
May 2005 to June 2006. Sputum specimens and demographic data were collected with 
informed consent. 
 
5.2.2. LABORATORY PROCESSING OF SPUTUM SPECIMENS 
 
Specimens were decontaminated using the NALC-NaOH method. The deposit was 
aliquoted into 4 portions, 3 of which were stored at -70°C. Auramine smear microscopy, 
culture on MB 7H11, MGIT and the proportion method of drug susceptibility testing 
were performed on the fourth aliquot. 
 
5.3. RIFOLIGOTYPING ASSAY/RIFO ASSAY  
 
5.3.1. SEQUENCE OF OLIGONUCLEOTIDE PROBES 
 
The oligonucleotide probe sequences were designed using the OligoAnalyser 3.0 
(www.basic.northwestern.edu/biotools/oligocalc.html) from the wild type sequence of 
H37Rv of M. tuberculosis obtained at GenBank while the mutant probes were designed 
using the sequences obtained by sequencing. Probe sequences were designed such that 
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they possessed similar theoretical melting temperatures (52.4< Tm < 62.8 °C) to facilitate 
their use in a single hybridisation assay. Fifteen oligonucleotide probes with a C6 
aminolink at the 5” end (Whitehead Scientific Inc) were used to produce a macroarray 
(Table 5.1). The first five probes represented a scanning array to detect the wildtype 
genotype and the remaining 10 analysed loci associated with RIF resistance.  
 
Table 5.1 Sequences of the oligonucleotide probes immobilised on membrane 




WT1 rpoB 509-514 wt AGC CAG TCG AGC CAA TTC AT 57.3 0.8 
WT2 rpoB 514-520 wt TTC ATG GAC CAG AAC AAC CCG 57.5 1 
WT3 rpoB 521-525 wt CTG TCG GGG TTG ACC CG 58.6 25 
WT4 rpoB 524-529 wt TTG ACC CAC AAG CGC CGA 60.3 800 
WT5 rpoB 530-534 wt CTG TCG  GCG CTG GGG 60 12.5 
MT1 rpoB 510CAT AGC CAT CTG AGC CAA TTC AT 54.9 800 
MT2 rpoB 511CCG AGC CAG CCG AGC CAA TTC AT 59.9 50 
MT3 rpoB 516TCC TTC ATG TCC CAG AAC 55.0 1600 
MT4 rpoB 516TAC TTC ATG TAC CAG AAC 52.4 50 
MT5 rpoB 516GTC TTC ATG GTC CAG AAC 55.0 12.5 
MT6  rpoB 516GGC TTC ATG GGC CAG AAC 58.0 25 
MT7  rpoB 526GAC TTG ACC GAC AAG CGC CGA 60.1 150 
MT8 rpoB 526TAC TTG ACC TAC AAG CGC CG 55.4 1 
MT9 rpoB 531TTG CTG TTG GCG CTG GGG 57.2 6 
MT10 rpoB 533CCG GCG CCG GGG CCC 62.8 6 
WT/wt = wildtype, MT= mutant, * = concentration in pmoles. Nucleotides bolded and 
underlined indicate mutation point on the codon 
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5.3.2. PREPARATION OF MEMBRANE  
 
A Biodyne C membrane (Pall Biosupport) was activated by incubating with 16% (wt/vol) 
EDAC (Sigma) at room temperature for 15 min. The membrane was rinsed with tap water 
and placed together with a PC200 support cushion (Immunetics, Cambridge, Mass) and 
cling wrap in a Miniblotter 45 manifold (Immunetics). The oligonucleotide probes with a 
C6 aminolink at the 5΄ end (Whitehead Scientific), were diluted in 0.5 M NaHCO3 (pH 
8.4) at a concentration ranging from 0.8 to 1600 pmol/150µL. These were applied on the 
activated membrane in a macroarray format by filling the slots of the miniblotter MN45 
(Figure 5.3).  
 
The probes were allowed to bind for 1 min at room temperature, after which the probe 
solution was aspirated from the slots. The membrane was removed from the manifold 
using forceps and was then inactivated by incubating with 100 mM NaOH at room 
temperature for 10 min. This was followed by washing in 2 x SSPE containing 0.1% SDS 
for 10 min at 50°C with shaking. The membrane was stored in 20mM EDTA in a sealed 
plastic bag at 4°C to avoid dehydration until required. Optimal probe concentrations were 
determined by binding varying concentrations of the probe such that all the probes 




Figure 5.3 Membrane with immobilised oligonucleotide probes. Red lines represent 
wildtype probes and blue lines represent mutant probes.  
 
 
5.4. DNA EXTRACTION 
 
Extraction of DNA from clinical specimens and isolates was performed as described in 
chapter 3 section 3.5.1 and chapter 4 section 4.2.3 respectively.  
 
 
5.5. AMPLIFICATION OF rpoB GENE  
5.5.1.  CLINICAL ISOLATES 
 
For the detection of the rpoB genotype, PCR was performed as described by van der 
Zanden et al, 2003 using the primers described in section 4.2.5 to amplify a 437 bp 
fragment of the rpoB gene using the reaction mixture shown in Table 5.2. The reverse 
primer was biotinylated at the 5’ end. 
1    2     3     4    5    6     7    8     9   10   11  12   13  14  15 
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   Table 5.2 Reaction mixture for amplifying the rpoB gene from DNA   of    
   clinical isolates 
PCR reagent Volume  (µL) 
50 pmol rpoB-for1 primer 6.9 
50 pmol rpoB-rev1primer 5’ biotinylated 6.9 
14.5 mM Tris (pH 9.0) 9 
500 mM KCl 5.5 
25mM MgCl2  5.0 
0.2 mM dNTP’s 1.3 
Taq DNA polymerase 0.2 
Water 19.2 
DNA 1 
Total reaction 55 
 
Cycling was performed by incubation for 3 min at 96°C followed by a touch   
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 Table 5.3 Cycling conditions for amplification of the rpoB region 
Step Time (min) Temperature (°C) No. of cycles 


























































5.5.2. CLINICAL SPECIMENS  
 
Amplification of a 437 bp fragment of the rpoB gene from DNA extracted directly from 
sputum specimens (van der Zanden et al, 2003) was performed with modifications shown 
in Table 5.4 and thermal cycling was performed as described in Table 5.3. 
 
 
Table 5.4 Modified PCR reaction mixture for amplifying the rpoB gene in 
DNA from sputum specimens 
PCR reagent Volume  (µL) 
50 pmol rpoB-for1 primer  6.9 
50 pmol rpoB-rev1 primer 5’ biotinylated  6.9 
14.5 mM Tris (pH 9.0), 7.9 
500 mM KCl 5.5 
25mM MgCl2, 7.7 
0.2 mM dNTP’s 1.3 











5.6. OPTIMISATION OF HYBRIDISATION AND WASHING 
CONDITIONS FOR CLINICAL ISOLATES AND SPECIMENS OF M 
tuberculosis  
 
Ten and thirty microliters of PCR products respectively of clinical isolates and specimens 
were diluted in 150µL and 130 µL of 2 x SSPE/0.1% SDS (Appendix I). After 
denaturation at 100°C for 10 min, the DNA was chilled on ice. It was then applied on to 
the membrane in the miniblotter, in a direction perpendicular to the immobilised 
oligonucleotides. The assay was optimised by testing different hybridisation temperatures 
(55°C, 58°C, 60°C and 65°C) followed by aspiration of excess PCR product and washing 
at temperatures of 2°C higher to increase stringency. This stringency made it unlikely that 
sequences with two or more mismatches or sequences with insertion/deletions will 
hybridise to the probes and produce non-specific signals.  
 
After washing twice in 2 x SSPE/0.5% SDS at temperatures ranging from 57 to 67°C, the 
membrane was incubated in 10 ml of 2 x SSPE /0.5% SDS (Appendix I) containing 1.25 
U streptavidin-peroxidase conjugate at 42°C for 45 min. This was followed by washing 
twice in 2 x SSPE/0.5% SDS at 42°C for 10 min and twice in 2 x SSPE (Appendix I) at 
room temperature for 5 min. The optimal hybridization temperature was found to be 58°C 
and washing was done at 60°C (increased by 2°C to increase stringency). The membrane 
was used up to 9 times before the signals became faint and then considered unusable. 
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5.7. DETECTION OF HYBRIDISED DNA 
 
The hybridised DNA was detected using enhanced chemiluminescence (ECL) 
(Amersham) under red safety light. After exposure to detection reagents one and two, 
the membrane was initially exposed to a light sensitive ECL Hyperfilm (Amersham) 
for 20 min. Subsequent exposures were increased to 60 min to increase the intensity of 
the signals. Susceptible strains were expected to hybridise with wild type probes but 
with none of the resistant probes, while the resistant strains would hybridise with the 
mutant probe but not its corresponding wild type probe. Strains would also be 
characterised as resistant, if they did not hybridise with any one of the wild type 
probes and with none of the mutant probes, assuming that the probe with that 
particular mutation has not been immobilised. 
 
5.8. INTERPRETATION OF RESULTS 
 
(i) Presence of a mutation defined an isolate or specimen as resistant to RIF. This 
was characterized by absence of a hybridization signal for one or more of the 
wildtype probes and presence of a signal for one or more of the mutant probes. 
However, absence of a hybridization signal for one of the wildtype probes and no 
hybridization with any of the mutant probes was also defined as resistance as this 
could mean that a different mutation to that of the immobilised probe was present.  
(ii) Absence of a mutation defined an isolate or specimen as susceptible to 
Rifampicin. This was characterized by presence of a hybridization signal for all 
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the wildtype probes and absence of a hybridization signal for all the mutant 
probes. 
(iii) An isolate or specimen that gave a hybridization signal for all the wildtype probes 
and a hybridization signal for one or more mutant probe was defined as 
discrepant. 
 
5.9. STATISTICAL ANALYSIS OF RESULTS 
 
The RIFO assay results were compared with those of the 1% proportion method of drug 
susceptibility testing as the gold standard. Comparison was also done between RIFO 
assay results of clinical isolates and that of clinical specimens.  SPSS version 15.0 (SPSS 
Inc. Chicago Illinois) was used to generate frequency tables and cross tabulations. 
Sensitivity, specificity, Predictive Positive Values (PPV), Negative Predictive Values 
(NPV) and their 95% confidence intervals were calculated using EpiCalc 2001 version 




5.10.1. SPUTUM SMEAR AND CULTURE RESULTS 
 
Of the 425 patients enrolled at KGV hospital between 2005 and 2006, 195 (46%) were 











































Figure 5.4  Smear and culture results of 425 patients hospitalised at KGV hospital between 2005  
and 2006 
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5.10.2. RIFOLIGOTYPING OF CLINICAL ISOLATES 
 
5.10.2.1. RIFO PATTERNS 
 
Of the 425 clinical specimens, 279 (65.6%) were culture positive. RIFO patterns (Figure 
5.5) were obtained in 258 (92%) of the isolates of M. tuberculosis while 19 (7%) RIFO 
was not done as DNA was unavailable and 2 (1%) gave no patterns. Ten mutations were 
detected in 219 isolates and 37 isolates did not have any mutations. Two isolates showed 
no hybridization with one wildtype probe and no hybridization with the corresponding 
mutant probes suggesting that a mutation different to the immobilised mutant probe was 
present. The mutations detected in the RIFO assay are listed in Table 5.5. The most 
common site of point mutation leading to an amino acid substitution was Ser531Leu 
(117/219, 53.4%). 
 
 Five double mutations were found in 25 isolates involving codons Glu510Hist, 
Leu511Pro, Asp516Gly, Asp516Tyr, Asp516Ser and 533, while 1 isolate showed a triple 
mutation in codon Asp516Val, Ser531Leu and Leu533Pro (Appendix III). Thirteen 
isolates showed discrepant results i.e. hybridization signal for all the wild type probes and 
in addition hybridization signal for one or more mutant probes.  When culture RIFO 
assay results were compared to sequencing results, 197 of the 279 were comparable as 82 
isolates were not sequenced. Of the 197 comparable to sequencing results, 180 (91.4%) 
were concordant, 8 (4%) were discordant and 9 (4.6%) were discrepant (hybridization 
signal for all wildtype and one or more mutant probes). 
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Figure 5.5 RIFO assay results for detection of mutations in clinical isolates. Lanes 1 to 5 across contain 
oligonucleotide probes corresponding to the wildtype sequence of the rpoB gene and lanes 6 to 11 contain the mutant 
oligonucleotide probes. Lanes 1 and 10 vertically: mutations in codon 526 from CAC to GAC. Lanes 2 and 3: 
mutation in codon 526 from CAC to TAC. Lanes 7, 8 and 9: double mutations 511CCG/516TAC, 511CCG/516TCC 
and 510CAT/516TAC respectively. Lanes 14, 16, 21, 30, 31, 37 and 40: mutation 516GTC. Lanes 28 and 38: 
mutation 533CCG. Lanes 30 and 41: discrepant results. Lane 30: signals for all the wildtype probes as well as signal 
for 511CCG and 516GTC. Lane 41: no signal for WT5 and signals for 531TTG and 533CCG.  Lane 17: no pattern. 
Lane 42 no pattern but this was a negative control. Lane 39: signals for all of the wildtype probes and no signals for 
all the mutant probes and this was a positive control. The rest of the lanes showed mutation 531TTG which is the 
most frequently found mutation.  
 
 100 
Table 5.5 Frequency of mutations detected by the RIFO assay in isolates of M. 
tuberculosis 













No mutation*/516TAC 1 
No mutation*/516GGC 1 
No mutation*/516GTC 2 
No mutation*/531TTG 3 
531TTG/533CCG/516GTC 1 
No mutation*/516GTC/531TTG 3 
No mutation*/526GAC/531TTG 3 
* hybridization signal for all wild type probes 
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5.10.2.2. COMPARISON OF RIFO PATTERNS TO DST 
 
Of the 279 clinical isolates, 241 (88.6%) had RIFO assay results that could be compared 
to RIF drug sensitivity results performed by the proportion method (Table 5.6). Of these, 
217 were resistant to RIF by the RIFO assay. RIF resistance by both DST and RIFO 
assay was present in 206 of 224 RIF resistant, demonstrating a sensitivity of 92% [CI: 
95%, 0.87, and 0.95]. The specificity (35%) [CI: 95%, 0.15 and 0.61] of the assay was 
low, with 6 of 17 drug susceptible strains correctly identified as sensitive. The positive 
predictive value was 95% [CI: 95%, 0.91 and 0.97] and negative predictive value was 
25% [CI: 95%, 0.11, 0.47]. 
 
Table 5.6 RIFO culture results compared to DST 
DST RIFO ASSAY 
RESISTANT SUSCEPTIBLE 
TOTAL 
RIFR 206 11 217 
RIFS 18 6 24 
TOTAL 224 17 241 




5.10.2.3.  ANALYSIS OF DISCREPANT RESULTS BETWEEN 
PROPORTION METHOD OF DST AND RIFO ASSAY 
 
Sequencing was performed for 25 isolates that were either previously sequenced and 
produced discrepant results from the RIFO assay or not. Thirteen of these were sensitive 
by the proportion method and resistant by RIFO assay. Eleven of the 13 were not 
sequenced initially. Subsequent sequencing showed concordance of mutations with RIFO 
assay in 10 isolates. Additionally, 2 new mutations were identified (526CTC and 505 
CTC) in 2 previously unsequenced isolates. The sequencing chromatogram was 
suggestive of the presence of a mixed infection/ population of bacilli in the eleventh 
isolate. The remaining 2 were resistant by both sequencing and RIFO assay; however 
subsequent sequencing gave a mutation different to that of initial sequencing and RIFO 
assay.  No mutation was observed for the last isolate thus suggesting RIF sensitivity. 
 
Twelve isolates were RIF resistant by DST, and the initial sequencing was either not 
performed or discordant with the RIFO assay. Of these, 11 that were previously 
sequenced were concordant by the RIFO assay and the second sequencing. This suggests 
that the results of the first sequencing were incorrect. The second sequencing confirmed 
that the twelfth isolate that had not been previously sequenced had a mutation that was 
concordant with the RIFO assay. No hybridization signal was obtained for the wild type 




5.10.3. RIFOLIGOTYPING OF SPUTUM SPECIMENS 
 
5.10.3.1. RIFO PATTERNS 
 
Of the 425 sputum specimens that were rifoligotyped, 21 were excluded from the analysis 
as 10 were contaminated, 4 were MOTT and 7 although culture was positive, no DST 
results were available. RIFO patterns were produced for 3 of the contaminated, and 4 
without DST. RIFO patterns were not obtained for all 4 MOTT.  
 
RIFO patterns were obtained for 236 (58.4%) sputum specimens and no patterns were 
obtained for 168 (41.6%). Figure 5.6 represents an example of the RIFO assay results 
obtained from sputum specimens.  Of the 236, 32 specimens could not be included in the 
analysis as 15 were smear and culture negative, 7 were smear positive but culture was 
negative thus no DST results were available, 10 produced discrepant patterns which 
included signals for all wildtype probes and in addition one or more mutant probe either 
with culture RIFO or with sputum RIFO results. The remaining 204 (50.5%) produced 
RIFO patterns that were analyzable. Of the 168 specimens that did not produce RIFO 
patterns, 142 were smear negative while 26 were smear positive. Of the 142 that were 
smear negative, 108 were culture negative and 34 were culture positive. Of the 26 that 





























































 Figure 5.6 RIFO assay results for detection of mutations in sputum specimens with Chelex 
extracted DNA. Lanes 1 to 10 and lane 43: clinical isolates with all the mutations obtained by 
sequencing and H37Rv respectively and served as positive controls for the mutations. Lane 32: 
no mutation pattern. Lanes 13, 25, 31, 37, 38 and 41: mutation 531TTG. Lane 20: no 
hybridization for WT4 probe but no signal for mutant probe indicating that another mutation 
not targeted could be present. Lanes 24 and 34: mutations 533CCG and 516GTC respectively. 
Lane 36: double mutation 516GGC/533CCG. The rest of the lanes showed either incomplete 
patterns (these were repeated for better results) or no patterns at all. 


































































Table 5.7 Frequency of mutations detected by the RIFO assay in sputum specimens 












No mutation*/531TTG 3 
531TTG/533CCG/516GTC 2 
No mutation*/511CCG/516TCC 1 
No mutation*/526GAC/531TTG 1 
No mutation*/526TAC/531TTG 1 




5.10.3.2. COMPARISON OF SPUTUM RIFO ASSAY RESULTS TO 
DST 
 
DST of clinical isolates was compared with RIFO assay results of the 204 clinical 
specimens (Table 5.8). The RIFO assay was able to correctly identify mutations in 176 of 
the 188 RIF resistant samples, thus demonstrating a sensitivity of 94 % [95% CI: 0.89, 
0.97]. The specificity of the RIFO assay on clinical specimens was low with only 6 of the 
16 being correctly identified as RIF susceptible (specificity 38% [95% CI: 0.16, 0.64]). 
The positive predictive value was 95% [CI: 95%, 0.91 and 0.97] and negative predictive 
value was 33% [CI: 95%, 0.14, 0.59]. 
  
 
Table 5.8 Sputum RIFO assay results compared to DST 
CULTURE RIFO SPUTUM RIFO 
ASSAY RESISTANT SUSCEPTIBLE 
TOTAL 
RIFR 176 10 186 
RIFS 12 6 18 
TOTAL 188 16 204 
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5.10.3.3. PERFORMANCE OF THE RIFO ASSAY ON SPUTUM 
SPECIMENS 
 
The performance of RIFO assay on sputum specimens was evaluated using the smear 
grading results (Table 5.9). RIFO patterns were obtained in a range of 84 - 95% of all 
smear positive specimens that produced RIFO patterns (56 of 65, 86% of PSC; 29 of 
34, 85.3% of P1-10; 43 of 51, 84% of P11-20 and 55 of 58, 95% of P>20) including 
those with scanty and one plus AFBs. Of the 84 smear negative and culture positive 
45 (53.6%) gave RIFO patterns. Of the 122 smear negative and culture negative 15 
(12.3%) gave RIFO patterns. 
 
Table 5.9 Performance of the RIFO assay compared to smear and culture results 
N= 198 
RIFO PATTERNS OBTAINED FOR: 
SMEAR GRADING 
CULTURE POSITIVE CULTURE NEGATIVE 
PSC 51  5  
P1-10 28  1 
P11-20 42  1 
>20 54  1 
PSC positive scanty = 2-10 AFB per smear; P1-10 = 10-100 per 100 fields; P11-20 
10-100 AFB per fields; P>20 = >100 AFB per field. 
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5.10.4. COMPARISON OF RIFO ASSAY BETWEEN SPUTUM 
SPECIMENS AND CLINICAL ISOLATES  
 
The RIFO assay results of 202 (50%) of the 404 specimens were comparable between 
sputum specimens and clinical isolates (Table 5.10). Of these, 174 clinical isolates were 
resistant while 28 were susceptible to RIF by RIFO assay. The RIFO assay was able to 
detect 167 of the 174 resistant and 16 of the 28 susceptible samples, thus giving a 
sensitivity and specificity of 96% (CI: 95%, 0.92, 0.98] and 57% [CI: 95%, 0.37, 0.75] 
respectively. The positive predictive value was 93% [CI: 95%, 0.88 and 0.96] and the 
negative predictive value was 70% [CI: 95%, 0.47, 0.86] 
 
 
Table 5.10 Sputum RIFO results compared to Culture RIFO results 
CULTURE RIFO ASSAY SPUTUM RIFO 
ASSAY RIFR RIFS 
TOTAL 
RIFR 167 12 179 
RIFS 7 16 23 




In this study, an in-house RIFO assay was optimized for the detection of the 10 
commonest mutations in the rpoB gene that are associated with RIF resistance in M. 
tuberculosis specifically in KZN. These mutations were first determined by sequencing 
the hot spot region, codons 507 to 533 since they vary widely according to geographic 
location (Cavusoglu et al, 2002, Mokrousov et al, 2004, Jou et al, 2005).  
 
The significance of prior sequencing for modification of the RIFO assay for application 
in different regions is evident from studies undertaken by Senna et al, 2006 and 
Mokrousov et al, 2006. In an unmodified assay by the former, 55 (61%) of 90 isolates 
hybridized with mutant probes and 29 (32%) did not hybridize with the wildtype probes. 
In contrast, a high sensitivity (92.7%) was reported by Mokrousov et al, 2006 for the 
detection of mutations in Chinese isolates using a modified RIFO assay. This highlights 
the need to include mutant probes that are able to detect mutations prevalent in a specific 
area.   
 
In our study, mutations in the rpoB gene were correctly detected in 206 of 224 clinical 
isolates (92% sensitivity) that were confirmed as RIF resistant by the proportion method 
of DST. This was similar to that reported by Mokrousov et al, 2006. High sensitivies 
were also seen in studies done by Suresh et al, in 2006 and Jiao et al, in 2007 reporting 
sensitivities of 95.5 % and 91.5% respectively. High sensitivities were also reported for 
the detection of RIF resistance using other similar genotypic assays. The GenoType 
MTBDRplus showed sensitivities of 98.7% (Hillemann et al, 2007) and 91.7% (Lacoma 
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et al, 2008), whilst sensitivities of greater than 95% were achieved in several studies 
conducted in different countries using the INNO LiPA Rif.TB test (Cooksey et al, 1997, 
Martilla et al, 1998,  Hirano et al, 1999, Traore et al, 2000,   Bartfai et al, 2001).  
 
Alternative mechanisms of resistance such as mutations outside the 81-bp segment of the 
rpoB gene (Heep et al, 2001), bacterial efflux systems (Choudhuri et al, 1999, Banerjee 
et al, 2000; Putman et al, 2000) may be responsible for resistance in the remaining 8% of 
the resistant isolates with no mutations detected by the RIFO assay. Although some of 
these resistant isolates were sequenced again, their genotypic profile still showed a 
mutation, suggesting resistance. However, the DST was not repeated, and thus we could 
not rule out the possibility of false sensitive results by DST. These results concur with 
those of Mokrousov et al, 2006; Senna et al, 2006, Suresh et al, 2006 and Jiao et al, 2007 
who reported 4 (7.3 %) of the 55, 6 (6.7%) of 90 and 6 (8.5 %) of 71 respectively of the 
resistant isolates that do not possess mutations in the rpoB region.  
 
In sputum specimens, we observed a similar sensitivity (94%) to that of clinical isolates, 
demonstrating the ability of this technique to predict MDR directly in sputum specimens. 
Zhang et al (2003) performed RIFO assay on isolates recovered on ZN-stained slides and 
was able to obtain RIFO patterns in 57% of their slides. They did not calculate the 
sensitivity and the specificity of the RIFO assay for their study. However, sensitivities of 
96.2% (Nikolayevskyy et al, 2009), 98.6% (Hillemann et al, 2007) and 100% (Lacoma et 
al, 2008 and Miotto et al, 2006) were obtained for sputum smear positive specimens 
using the GenoType MTBDRplus. The sensitivity was reduced to 46.1% and 70.9% 
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respectively for smear negative sputum specimens (Lacoma et al, 2008, Miotto et al, 
2006).  
  
Mutations could not be detected directly in 12 (6.3%) of the 188 clinical specimens with 
RIF resistant isolates, possibly due to other resistant mechanisms discussed above. As 
with culture, the RIFO assay displayed low specificity when performed on sputum 
specimens, as only 6 of the 16 specimens susceptible by DST were correctly identified as 
being RIF susceptible. This gave the assay a reduced specificity of 38%. This was low 
compared to the specificity of the RIFO assay reported by Mokrousov et al, 2006 
(100%); Senna et al, 2006 (100%), Suresh et al, 2006 (99.1%) and Jiao et al, 2007 
(100%) for clinical isolates. Nikolayevskyy et al, in 2009 investigated the performance of 
the GenoType MTBDRplus in sputum specimens and reported a specificity of 90.7%.  
 
The low specificity on both culture and sputum specimens in our study may be 
attributable to several reasons. The presence of silent mutations in the rpoB gene is 
interpreted as resistant by the RIFO assay. Analysis of discrepant results by sequencing 
confirmed the presence of the identical mutations identified by the RIFO assay in 10 of 
11 isolates classified as susceptible by the proportion method. These strains may be one 
step from conversion to phenotypic resistance and therefore, may be classified as pre-
MDR, as most were INH monoresistant. Thus, the RIFO assay may be useful in the 
detection of pre-MDR-TB cases. However, the disadvantage would be an over diagnosis 
of MDR-TB cases if it is genotypically resistant and phenotypically susceptible.  The low 
specificity may also have resulted from an under representation of patients with drug 
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susceptible TB, since they were recruited from KGV hospital which is a referral hospital 
for MDR- and XDR-TB patients in Durban.This may be an important limitation which 
may have introduced bias in our study results. Therefore, this assay should be evaluated 
in an appropriate clinical setting to ascertain its’ true specificity.    
  
Heteroresistance may provide an alternative explanation for the low specificity observed 
in our study. Rinder et al, 2001, reported that the accuracy and reliability of drug 
susceptibility testing on clinical specimens is adversely affected by heteroresistance.  
They found that phenotypic results after primary isolation of pure cultures may not be 
representative of sputum specimens with mixed strains. In TB endemic regions such as in 
South Africa, concurrent mixed infections or mixed populations of drug resistant and 
drug susceptible bacilli are commonly encountered (Victor et al, 1999). 
  
We observed heteroresistance in 14 of the clinical isolates and 8 sputum specimens that 
showed a mixed profile by RIFO assay i.e. a wild-type and a resistant genotype. The 
isolates grown from these specimens were resistant with the proportion method of drug 
susceptibility testing. Similar observations were reported by de Oliviera et al, 2002 using 
the GenoType MDRTBplus assay. Thus, these assays demonstrate their usefulness in the 
detection of mutations in mixed populations. The sensitivity of detection of resistant 
subpopulations varied in different studies. Telenti et al, 1997 reported a mixed population 
of susceptible and resistant strains in 1 out of 42 RIF resistant isolates using the SSCP 
method. The INNO-LiPA test detected resistant subpopulations of strains at a level of 50-
75% of the total population (Cooksey et al, 1998). In this study, the RIFO assay could 
 113 
detect 6.4 % and 2.9% from clinical isolates and sputum specimens respectively of mixed 
populations.  
 
In agreement with most other studies, we found the most common mutations present at 
codons 516, 531 and 533. The most frequently occurring mutation in our study was the 
Ser-531-Leu, and this is in concordance with findings reported in other geographic areas 
(Telenti et al, 1993, Williams et al, 1998, Hirano et al, 1999, Scarpellini et al, 1999; and 
Cooksey et al, 2007). Mutations at codon 526 were less common, which was similar to 
the findings by Barnard et al, 2008, but in contrast to that reported in many other 
countries (Telenti et al, 1993, Williams et al, 1998, Hirano et al, 1999; Scarpellini et al, 
1999, Samper et al, 2005, and Cooksey et al, 2007). 
 
The majority of specimens that produced no RIFO patterns in this study were AFB smear 
negative. Van der Zanden et al, 2003 reported rifoligotyping patterns from positive ZN 
stained slides that contained 2+ or more AFB. However, in our study, between 85 - 95% 
of all positive smear specimens produced RIFO patterns, including those with scanty and 
one plus AFBs. We also observed some smear positive specimens that produced no RIFO 
patterns. This could have been due to insufficient numbers of bacilli present in the 
sputum specimens during aliquoting. We also found that some smear and culture negative 
sputum specimens produced RIFO patterns that may have resulted from the presence of 
uncleared dead bacilli as most of the specimens were collected from patients who were 
already on TB treatment.   
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Rapid, cost effective drug susceptibility testing is crucial for reducing nosocomial and 
community transmission of TB, especially MDR and XDR-TB. Developing countries, 
including those in Sub-Saharan Africa, Asia and Eastern Europe experience the highest 
burden of TB, including MDR and XDR-TB (WHO, 2009). The incidence of TB in South 
Africa is currently the fifth highest in the world, with a high number of XDR-TB cases 
reported in the province of KZN (Gandhi et al, 2006). Such rapid results would be highly 
beneficial in regions with high-HIV prevalence, such as in South Africa, where a large 
proportion of patients with HIV-TB co-infections are smear negative.  
 
The use of this macro-array format on clinical specimens or isolates as a first line adjunct 
to phenotypic DST is a great advantage, particularly in laboratories that already perform 
spoligotyping. Both assays utilize the same equipment, technology and chemistry, and are 
easy to conduct. In addition, results are rapidly generated, within 48 hours after DNA 
extraction, and large numbers of samples, up to 43, can be processed at a time.  
 
A further attractive feature is that the membrane can be chemically treated for multiple 
usage. In this study, it was re-used 9 times. These features significantly reduce the cost 
per sample, which was calculated to be R6, 81 thus rendering it more cost effective than 
the commercial macroarray methods such as the INNO LiPA Rif.TB (US$45 per sample, 
Morgan et al, 2005) and /or the GenoType MTBDRplus assays (R116 per sample) 
currently used in reference laboratories in Southern Africa (Bernard et al, 2008).  
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Although commercial assays such as the GenoType MTBDRplus and the GeneXpert 
MTB/RIF have been endorsed by the WHO and are currently being used in reference 
laboratories in South Africa, they are expensive and only a limited number of samples 
can be tested at a time. Also, only a limited number of selected mutations can be detected 
by these assays for prediction of RIF resistance. In contrast, the in house RIFO assay 
detects mutations specific for a geographic region and also allows for modification of the 
assay as new mutations are discovered. One technician can be employed and be dedicated 
to this assay and can process at least 43 specimens at once. The thousands of rands that 
can be saved from using this assay as an alternative to the expensive commercially 
available assays can be used in patient care and management of the TB disease. 
Development of this assay for direct detection of RIF resistance in sputum specimens is 
an initial step towards incorporating other mutations which are markers of resistance for 





6. DISCUSSION AND CONCLUSION 
 
KZN province has one of the highest TB burdens in the world, including MDR and XDR-
TB as was highlighted in Tugela Ferry in 2005 ( Ghandi et al, 2006).  There is an urgent 
need for diagnostic tests that can rapidly identify TB and detect drug resistance in M. 
tuberculosis directly from clinical specimens in order to reduce transmission rates and 
reverse these trends. Molecular assays have shown tremendous potential to fulfill the 
requirements of rapid diagnostics.  
 
Molecular tests based on DNA extracted from cultured isolates require primary isolation 
from clinical specimens which adds on to diagnostic delays by at least 3 or more weeks. 
This may be overcome by performing direct detection of M. tuberculosis from clinical 
samples.  However, the presence of inhibitors in clinical specimens such as sputum 
reduces the sensitivity of molecular assays. In this study, we investigated four DNA 
extraction methods and found the Chelex extraction method to be the most optimal in 
removing PCR inhibitors. It was also cost effective with respect to price, ease of 
performance and shelf life of the reagents. The Chelex method was then used to extract 
DNA directly from sputum samples to optimize an in-house reverse line hybridization 
assay for detecting mutations in the rpoB region of M. tuberculosis.  
 
Sequencing of rpoB gene of the clinical isolates in our study revealed the presence of 11 
mutations, with the highest frequency of mutations occurring in the 531 codon 
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(TCG→TTG resulting in Ser→Leu) as was reported in numerous studies. This was 
followed by 516(GAC→GTC causing a Asp→Val) and 533(CTG→CCG; Leu→Pro). 
We compared the mutations obtained in our study isolates to those of Kiepiela et al, in 
KZN strains in 1998, and did not find 50% of the mutations that were present in their 
study. It is possible that these mutations were associated with a fitness cost that reduced 
the survival of strains harbouring such mutations approximately a decade later.  
 
Literature has consistently demonstrated that mutations in the rpoB region are not 
detected in all resistant strains of M. tuberculosis. Similarly, in our study, mutations in 
this locus were not detected in some isolates by sequencing of the rpoB region, even 
though they were resistant by the proportion method of DST. This can be attributed to the 
presence of mutations outside the resistant locus targeted or other mechanisms of 
resistance such as efflux pumps that have been demonstrated in other bacterial species 
and are yet to be elucidated in M. tuberculosis. The high percentage (9.7%) of isolates 
lacking mutations represents an impediment to molecular drug resistance testing. 
Therefore, although molecular methods may significantly enhance the rapid detection of 
mutations associated with drug resistance, they should be used as an adjunct to, but not 
replace phenotypic methods. 
 
The reverse line assay (RIFO assay) was modified to detect 10 specific mutations 
identified among the KZN isolates, using Chelex extracted DNA directly from clinical 
specimens. The accuracy (91%) of mutation detection from clinical samples was 
determined by comparison with mutations detected in isolates cultured from the same 
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specimens. The sensitivity of the RIFO assay in both clinical isolates and sputum 
specimens was high (92 and 94% respectively) compared to the phenotypic proportion 
method as the gold standard. However, the low specificity (35 and 38% respectively) for 
both isolates and sputum specimens is attributable to the presence of silent mutations in 
77% of samples as confirmed by sequencing of the rpoB gene of the susceptible strains 
whose RIFO assay results were discrepant with DST. These findings highlight the 
significance of silent mutations in genotypic assays in over estimation of MDR cases. 
However, they may signify the prelude to phenotypic RIF resistance and thus true MDR, 
which may be confirmed by testing serial isolates of patients in a longitudinal study over 
time.   
 
The limitation of this study is that the in-house RIFO assay was not evaluated in a clinical 
setting with a large number of patients with drug susceptible TB and this may also have 
contributed to the lower specificity. Although relatively easy to perform, the assay is time 
consuming and can only be performed within a laboratory setup, requiring a certain level 
of molecular biology expertise.  
  
Despite the low specificity due to silent mutations and the limitations mentioned above, 
the in-house RIFO assay has numerous advantages. It is capable of detecting the 
commonest mutations specific to KZN and is cheaper than commercially available assays 
(R 6.81 compared to R116 for the Haines test. Multiple samples (43) can be tested 
simultaneously and the membrane is robust so that it is re-usable up to 9 times, thus 
significantly reducing the costs. The modest equipment requirements such as a thermal 
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cycler, hybridization oven, waterbath, microcentrifuge and darkroom facility are 
generally available in a standard laboratory. The RIFO assay is rapid, and can be 
performed directly on sputum specimens to generate results within 3 days of specimen 
receipt. The high sensitivity enables prediction of RIF resistance and therefore MDR-TB 
in 3 days compared to the phenotypic gold standard. These attributes highlight the 
potential of this assay as a suitable, competitive alternative to expensive commercially 
available genetic based tests in poorly resourced developing countries with high TB 
burdens such as in Southern Africa. The Hains GenoType MTBDRplus would have 
missed the double mutations 516GGC/533CCG double and single mutation 533CCG 
which constituted almost 20% of our isolates.  
 
The WHO endorsed GenoType MTBDRplus and the GeneXpert MTB/RIF currently in 
use in reference laboratories in South Africa are expensive and can detect only a limited 
number of selected mutations for prediction of RIF resistance. The in house RIFO assay 
detects mutations specific for a geographic region and also allows for modification of the 
assay as new mutations are discovered. This assay can be further developed for the rapid 
detection of mutations associated with resistance to first and second line drugs. This will 
be a milestone in directly detecting XDR-TB. 
 
Future studies should be conducted in clinical settings to enroll more patients infected 
with drug susceptible TB to increase the specificity of the assay and to determine its cost 
effectiveness. Similar assays should be designed for the rapid detection of resistance to 
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Preparation of reagents 
 
10% SDS 
SDS       10 g 
Water       100 ml 
The SDS was dissolved in deionised water and stored at room temperature for up to 6 
months. 
 
Tris-Cl/Borate/EDTA (TBE Buffer 5X) 
Tris base (Sigma)    54 g 
 Boric acid (H3 BO3) (BDH)   27.5 g 
 0.5 M EDTA (pH 8.0)   20 ml 
Tris base and boric acid was dissolved in 800 ml distilled water.  EDTA was then added 
and the pH was adjusted to 8.0 with NaOH.  The buffer was autoclaved at 121°C for 15 




10 X TE Buffer (pH 8.0) 
100 mM Tris/HCl 
 10 mM EDTA 
 Tris    1.211 g 
 EDTA   0.3722 g 
Dissolve 1.211 g Tris in 80 ml of distilled water. Add 0.3722 g EDTA. Mix until it 
dissolves. PH to 8.0 with concentrated HCl. Make up to 100 ml in measuring cylinder. 
Autoclave at 121°C for 15 min. 
 
5 M NaCl 
NaCl   14.6 g 
Water   50 ml  
Dissolve NaCl in 45 ml distilled water with heating. Bring up to 50 ml. Autoclave at 
121°C for 15 min.  
 
CTAB/NaCl 
NaCl   4.1 g 
CTAB   10 g 
Water   100ml 
Dissolve 4.1 g of NaCl in 80 ml distilled water. Add 10 g of CTAB and heat solution at 










Dissolve 10 mg (0.01 g) of Proteinase K in 1 ml distilled water. Store at -20C. Prepare 
just before use. 
 
SDS/Proteinase K mix (per sample) 
 
5µl Proteinase K (10mg/ml) 
70µl 10% SDS 










70 ml absolute ethanol 
 30 ml sterile distilled water 
 
0.5 M EDTA 
EDTA    186.1 g 
Water    800 ml 
Add 186.1 g of EDTA to 800 ml of water. Stir vigorously with a magnetic stirrer; adjust 
pH to 8.0 with NaOH pellets (~20g). Bring volume up to 1000 mls. 
 
 Inhibitor Removal Solution 
Guanidium thiocynate (GITC) 30 g 
 EDTA     0.47 g 
 Sarcosyl    0.25 g 
 L- mercaptoethanol   0.78 ml 
 Tris/HCl (pH 7.5)   5 ml 
Dissolve GITC, EDTA, sarcosyl and L-mercaptoethanol in 45 ml water. Add to 5 ml of 
Tris/HCl pH 7.5. (NB: Stable for 2 months at room temperature if stored in dark and 
airtight container. This solution is prepared in the fume hood and GITC- containing waste 




Chelex    1.2 g 
Tween 20   36µl 
Triton X 100   3.6µl 
Add distilled water to make a final volume of 10 ml. 
 
Acid washed silica 
Silica (SiO2)   6 g 
Water    50 ml 
Add 6 g of SiO2 in 50 ml distilled water and vortex thoroughly. Allow to settle 24 hrs at 
room temperature. Remove 43 ml of upper liquid by aspiration and fill up to 50 ml. 
Allow to settle for 5 hrs at room temperature. Remove the upper liquid by aspiration. Add 
60 l of concentrated HCl to adjust the pH to pH 2. Aliquot 4 mls in small bottles and 
autoclave. Store at room temperature in the dark. 
 
Lysis Buffer (L6) 
Guanidium thiocynate    24 g 
0.1 M Tris/HCl pH 6.4   20 ml 
0.2 M EDTA pH 8.0    4.4 ml 
Triton X 100     500 µl 
Dissolve 24 g in of GITC in 20 ml of 0.1 M Tris/HCl, pH 6.4 (Heat at 60C to dissolve). 
Add 4.4 ml of 0.2 M EDTA (pH 8.0) and 500 µl of Triton X 100 (mix by inverting). 
Store at room temperature, in the dark (Stable for 3 weeks).  
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Wash Buffer (L2) 
Guanidium thiocynate    24 g 
0.1 M Tris/HCl pH 6.4   20 ml 
Dissolve 24 g GITC in 20 ml of 0.1 M Tris/HCl pH 6.4 at 60 C. Store at room 
temperature, in the dark (Stable for 3 weeks). 
 
M Tris/HCl pH 6.4 
 
Tris   1.211 g 
Water   100 ml 
Dissolve 1.211 g of Tris in 80 ml of distilled water. Adjust pH to 6.4 with concentrated 
HCl. 
 
0.1 M EDTA pH 8.0 
EDTA   37.77 g 
Water   500 ml 
Dissolve 37.22 g of EDTA in 400 ml of distilled water. Adjust pH with NaOH to 8.0. 
 
3M Sodium Acetate 
Sodium Hydroxide   40.82 g 
Water     100 ml 
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Dissolve 40.82 g of NaOH pellets in 80 ml of distilled water. Adjust pH to 5.2 with 
glacial acetic acid. Adjust volume to 100 ml and sterilize by autoclaving at 121 C for 15 
min. 
 
500 mM NaHCO3 
NaHCO3   4.2 g 
Water    80 ml 
Dissolve 4.2 g of NaHCO3 in 80 ml of distilled water. Adjust pH to 8.4 and make up to 
100 ml by adding water. Store at room temperature for no longer than one year  
 
16% (w/v) 1- ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) 
EDAC    1.6 g 
Water    8 ml 
Dissolve 1.6 g of EDAC in 8 ml of distilled water. Once dissolved adjust volume to 10 
ml with distilled water. Prepare fresh before use. 
 
20 x SSPE 
Na2HPO4*2H2O   17.8 g 
NaCl     105.12 g 
EDTA     3.7 g 
Place in magnetic stirrer; adjust pH to 7.4 using NaOH and autoclave. Store at room 







No. Strain no. Sensitive Resistant Sequencing results 
1  R01 O K I R E S  531TTG 
2  R02 E O K I R S 531TTG 
3  R05 E O K I R S 526GAC 
4  R09 E O K I R S 531TTG 
5  R10 E O K I R S 531TTG 
6  R11 E O K I R S 531TTG 
7  R12 E O K I R S 531TTG 
8  R15 E O K I R S 531TTG 
9  R17 E O K I R S 531TTG 
10  R20 E S O K I R 531TTG 
11  R21 E O K I R S 531TTG 
12  R22 E O K I R S 516GTC 
13  R23 E S O K I R 516GTC 
14  R25 E O K I R S  516GTC 
15  R26 E S I R O K 516GGC/533CCG 
16  R29 E S O K I R 531TTG 
17  R30 E I R S O K  531TTG 
18  R32 E O K I R S 531TTG 
19  R34 E O K I R S  516GTC 
20  R35 E O K I R S 533CCG 
21  R38 E O K I R S 531TTG 
22  R39 E O K I R S  526GAC 
23  R40 S O K I R E 533CCG 
24  R42 E S O K I R 516GTC 
25  R43 S O K I R E 533CCG 
26  R44 E O K I R S 531TTG 
27  R46 E S O K I R 531TTG 
28  R47 E O I R S K 533CCG 
29  R48 R E S O K I 531TTG 
30  R50 E O K I R S 531TTG 
31  R53 E O K I R S 516GTC 
32  R55 E S O K I R  516GTC 
33  R56 E S O K I R 531TTG 
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34  R57 E S O K I R 531TTG 
35  R58 E O K I R S 531TTG 
36  R59 E O K I R S  516GTC 
37  R60 E O K I R S 516GTC 
38  R64 E O K I R S 531TTG 
39  R65 E O K I R S 516GTC 
40  R66 E S O K I R 531TTG 
41  R69 E O K I R S 531TTG 
42  R70 E O K I R S 531TTG 
43  R83 E O K I R S 531TTG 
44  R86 E O K I R S 531TTG 
45  R91 E O K I R S  531TTG 
46  R94 E O K I R S 516GTC 
47  R102 I E S O K R 533CCG 
48  R108 E S O K I R 533CCG 
49  R109 E O K I R S 531TTG 
50  R113 E O K I R S 531TTG 
51  R114 O K I R S E 533CCG 
52  R116 E S O K I R  526TAC 
53  R123 E S O K I R 533CCG 
54  R134 E O K I R S  526GAC 
55  R137 E S O K I R 516GTC 
56  R138 E S O K I R 531TTG 
57  R139 E S O K I R 516GTC 
58  R140 E S O K I R 531TTG 
59  R141 E O K I R S 516GTC 
60  R143 E S O K I R  531TTG 
61  R145 E S O K I R 531TTG 
62  R146 E S O K I R  516GTC 
63  R154 E O K I R S 531TTG 
64  R157 E S O K I R 533CCG 
65  R160 O K I R S E 531TTG 
66  R164 O K I R E S  531TTG 
67  R171 I R E S O K   531TTG 
68  R207 E S O K I R  531TTG 
69  R208 E S O I R O 526TAC 
70  R209 E O K I R S  516GTC 
71  R211 E O K I R S  531TTG 
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72  R212 E S I R O K 516GTC 
73  R213 E O K I R S 531TTG 
74  R214 E O K I R S  531TTG 
75  R216 E O K I R S 531TTG 
76  R223 E S O K I R 531TTG 
77  R225 E O K I R S  516GTC 
78  R226 E O I R S K 531TTG 
79  R230 E S O K I R 531TTG 
80  R231 E O K I R S 531TTG 
81  R232 E O K I R S  531TTG 
82  R233 O K I R E S  526GAC 
83  R234 I R E S O K   531TTG 
84  R242 E O K I R S 531TTG 
85  R243 E S O K I R 533CCG 
86  R248 E O K I R S No mutation (s) 
87  R251 S I R E O K 516GGC/533CCG 
88  R253 E S I R O K 516GGC/533CCG 
89  R254 E O K I R S  516GTC 
90  R256 E O K I R S  516GTC 
91  R257 E S I R O K 516GGC/533CCG 
92  R268 O K I R E S 531TTG 
93  R269 E S O K I R 531TTG 
94  R271 E S O K I R  531TTG 
95  R273 E O K I R S  531TTG 
96  R276 E S O K I R 531TTG 
97  R277 E O K I R S  516GTC 
98  R281 E S O K I R  533CCG 
99  R283 E S O K I R 516GTC 
100  R284 E S O K I R 533CCG 
101  R285 E O K I R S 531TTG 
102  R287 E S O K I R 533CCG 
103  R293 O K I R E S 531TTG 
104  R298  E S O K  I R  531TTG/537GAT 
105  R299 E I R S O K  533CCG 
106  R300   I R E S O K 531TTG 
107  R301 E O K I R S 531TTG 
108  R303 E O K I R S  531TTG 
109  R309 E S O K I R 531TTG 
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110  R314 E S I R O K 516GGC/533CCG 
111  R325 E O K I R S 531TTG 
112  R327 E O K I R S 516GTC 
113  R328 E O K I R S 531TTG 
114  R332 E O K I R S 531TTG 
115  R334 E S O K I R 531TTG 
116  R336 E O K I R S 531TTG 
117  R339 E S I R O K 516GGC/533CCG 
118  R348 E O K I R S 531TTG 
119  R350 E O K I R S 516GGC/533CCG 
120  R352 E O K I R S 531TTG 
121  R364 E O K I R S 531TTG 
122  R373 E O K I R S 531TTG 
123  R375 E I R S O K 516GGC/533CCG 
124  R376 E S I R O K 516GGC/533CCG 
125  R377 E O K I R S 516GGC/533CCG 
126  R378 E O K I R S 531TTG 
127  R379 E S O K I R 516GTC 
128  R382 E O K I R S 531TTG 
129  R384 E S O K I R 531TTG 
130  R385 E O K I R S 531TTG 
131  R386 O K I R E S 531TTG 
132  R387 E S O K I R 531TTG 
133  R388 E O K I R S 531TTG 
134  R389 E S I R O K 516GGC/533CCG 
135  R391 E S O I R O 531TTG 
136  R392 E S O K I R 511CCG/516TAC 
137  R395 E S O K I R 531TTG 
138  R396 E S O K I R 531TTG 
139  R404 E O K I R S 531TTG 
140  R413 E S O I R K 531TTG 
141  R415 E S O K I R 511CCG/516TCC 
142  R417 E O K I R S 510CAT/516TAC 
143  R421 E O K I R S 531TTG 
144  R425 E S O K I R 526GAC 
145  R426 E S O I R K 533CCG 
146  R427 E S O K I R 531TTG 
147  R428 E S I R O K 516GGC/533CCG 
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148  R430 E O K I R S 531TTG 
149  R431 E O K I R S 531TTG 
150  R34 E S I R O K 516GGC/533CCG 
151  R437 E S O K I R 526TAC 
152  R443 O  I R E S K 531TTG 
153  R459 E S O K I R 531TTG 
154  R471 E O K I R S 531TTG 
155  R479 E O K I R S 531TTG 
156  R492 E S I R O K 531TTG 
157  R496 E S O K I R 531TTG 
158  R498 E S O K I R 531TTG 
159  R500 E S O K I R 531TTG 
160  R501 E O K I R S 516GGC/533CCG 
161  R502 E S I R O K 516GGC/533CCG 
162  R503 E I R S O K 516GGC/533CCG 
163  R504 E S I R O K 516GGC/533CCG 
164  R506 E I R S O K 516GGC/533CCG 
165  R507 S K I R E O 531TTG 
166  R510 E S O K I R 531TTG 
167  R514 K I R E S O 531TTG 
168  R524 E O K I R S 531TTG 
169  R525 E I R S O K 516GGC/533CCG 
170  R527 I E O K R S 531TTG 
171  R539 O K I R E S 531TTG 
172  R561 E O K I R S 531TTG 
173  R574 E O K I R S 531TTG 
174  R575 E O K I R S 516GTC 
175  R576 O I R E S K 531TTG 
176  R577 E O K I R S 531TTG 
177  R589 E S O K I R 531TTG 
178  R613 E O K I R S 526GAC 
179  R617 E O K I R S 516GTC 
180  R619 O K I R E S 531TTG 
181  R621 E O K I R S 533CCG 
182  R622 E O K I R S 516GGC/533CCG 
183  R626 E O K I R S 533CCG 
184  R627 E O K I R S 516GTC 
185  R629 E O K I R S 531TTG 
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186  R670 E O K I R S 531TTG 
187  R693 E O K I R S 531TTG 
188  R62 E S O I R K No mutation(s) 
189  R87 E S O K I R No mutation(s) 
190  R88 E O K I R S No mutation(s) 
191  R210 E S O K I R No mutation(s) 
192  R258 E S O K I R No mutation(s) 
193  R274 E S O K I R No mutation(s) 
194  R282 E S O K I R No mutation (s) 
195  R330 E S O K I R No mutation(s) 
196  R349 E S O K I R No mutation(s) 
197  R380 E O K I R S No mutation(s) 
198  R383 I R E S O K   No mutation(s) 
199  R400 I R E S O K   No mutation(s) 
200  R402 E S I R O K No mutation(s) 
201  R429 E S O K I R No mutation(s) 
202  R436 I E S O K R No mutation(s) 
203  R623 E S I R O K No mutation(s) 
204  R24 E S O K I R No mutation(s) 
205  R 49 E S O K I R No mutation(s) 
206  R52 R E S O K I No mutation(s) 
207  R61 E S O K I R No mutation(s) 
208  R67 E O K I R S No mutation(s) 
209  R79 I R E S O K   No mutation(s) 
210  R95 O K I R S E No mutation(s) 
211  R103 I R E S O K   No mutation(s) 
212  R104 I R E S O K   No mutation(s) 
213  R107 I R E S O K   No mutation(s) 
214  R117 E O K I R S No mutation(s) 
215  R125 I R E S O K   No mutation(s) 
216  R126 I R E S O K   No mutation(s) 
217  R127 I R E S O K   No mutation(s) 
218  R132 I R E S O K   No mutation(s) 
219  R149 E O K I R S No mutation(s) 
220  R152 I R E S O K   No mutation(s) 
221  R166 I R E S O K   No mutation(s) 
222  R167 I R E S O K   No mutation(s) 
223  R172 I R E S O K   No mutation(s) 
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224  R181 I R E S O K   No mutation(s) 
225  R186 I R E S O K   No mutation(s) 
226  R187 I R E S O K   No mutation(s) 
227  R196 I R E S O K   No mutation(s) 
228  R237 E S O K I R  No mutation(s) 
229  R252 E I R S O K  No mutation(s) 
230  R261 I R E S O K   No mutation(s) 
231  R262   I R E S O K No mutation(s) 
232  R267 I R E S O K   No mutation(s) 
233  R286 I R E S O K   No mutation(s) 
234  R288 I R E S O K   No mutation(s) 
235  R291 I R E S O K   No mutation(s) 













Sensitive Resistant Sequencing Culture RIFO results Sputum RIFO results 
R12 PSC 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R20 P11-20 2 wk + E S O K I R 531TTG 531TTG 531TTG 
R25 P1-10 3wk Sc E O K I R S 516GTC 516GTC 531TTG 
R9 P1-10 2 wk + E O K I R S 531TTG 531TTG No pattern 
R17 P11-20 2wk ++ E O K I R S 531TTG 531TTG 531TTG 
R28 NEG NEG NEG NEG ND ND No pattern 
R7 P1-10 6wk + failed to grow failed to grow ND ND 531TTG 
R1 P11-20 2wk Sc O K I R E S 531TTG 531TTG 531TTG 
R4 NEG NEG NEG NEG ND ND No pattern 
R14 NEG NEG NEG NEG ND ND No pattern 
R22 PSC 2 wk + E O K I R S 516GTC 516GTC 516GTC 
R27 NEG NEG NEG NEG ND ND No pattern 
R24 PSC 1wk Sc E S O K I R No mutation No mutation 533CCG 
R16 NEG NEG NEG NEG ND ND No pattern 
R11 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R6 P11-20 1wk Sc failed to grow failed to grow ND ND No pattern 
R2 NEG 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R13 NEG NEG NEG NEG ND ND No pattern 
R18 NEG 3wk Sc R E S O K I ND 516GTC No mutation 
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R23 P>20 2wk ++ E S O K I R 516GTC 531TTG 531TTG 
R19 P11-20 2wk ++ I R E S O K  ND No mutation No mutation 
R15 PSC 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R3 NEG NEG NEG NEG ND ND No pattern 
R8 NEG NEG NEG NEG ND ND No pattern 
R5 P1-10 2wk Sc E O K I R S 526GAC 526GAC 526GAC 
R21 P>20 2wk +++ E O K I R S 531TTG 531TTG 531TTG 
R10 NEG 3wk + E O K I R S 531TTG 531TTG 531TTG 
R26 PSC 2wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R30 NEG 3wk Sc E I R S O K 531TTG 531TTG No pattern 
R29 NEG 2wk Sc E O S K I R 531TTG 531TTG 531TTG 
R39 PSC 2wk Sc E O K I R S 526GAC 526GAC No pattern 
R44 NEG 3wk Sc E O K I R S 531TTG 531TTG No pattern 
R47 NEG 4wk Sc E O I R S K 533CCG 533CCG No pattern 
R34 NEG 2wk Sc E O K I R S 516GTC 516GTC 516GTC 
R52 PSC 1wk Sc R E S O K I No mutation No pattern 526? 
R57 NEG 2wk Sc E O S K I R 531TTG 531TTG No pattern 
R31 NEG NEG NEG NEG ND ND No pattern 
R59 PSC 2wk Sc E O K I R S 516GTC 516GTC 516GTC 
R36 NEG 6wk + R E O K I S ND 531TTG 531TTG 
R42 PSC 3wk Sc E S O K I R 516GTC 516GTC 531TTG 
R50 P11-20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R33 PSC NEG NEG NEG ND ND 533CCG 
R46 P1-10 2wk Sc E S O K I R 531TTG 531TTG  531TTG 
R55 NEG 2wk Sc E O S K I R 516GTC 516GTC No pattern 
 177 
R49 P>20 1wk Sc E S O K I R No mutation No mutation No 
mutation/526TAC/531TTG 
R32 NEG 1 wk Sc E O K I R S 531TTG 531TTG 526GAC 
R41 NEG MOTT NEG NEG ND ND No pattern 
R54 NEG 6wk Sc I R E S O K  ND No mutation No pattern 
R38 NEG 2wk + E O K I R S 531TTG 531TTG 531TTG 
R51 PSC 2wk Sc R E S O K I ND No mutation No mutation 
R37 NEG NEG NEG NEG ND ND No pattern 
R43 PSC 2wk Sc S O K I R E 533CCG 533CCG No pattern 
R35 NEG 1 wk Sc E O K I R S 533CCG 533CCG 531TTG 
R58 P11-20 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R53 P11-20 NEG E O K I R S 516GTC 516GTC 516GTC 
R40 NEG 2wk Sc E O S K I R 533CCG 533CCG 533CCG 
R45 NEG NEG NEG NEG ND ND No pattern 
R56 PSC 2wk Sc E S O K I R 531TTG 531TTG 531TTG 
R60 PSC 2wk Sc E O K I R S 516GTC 516GTC 516GTC 
R48 P11-20 2wk Sc R E S O K I 531TTG 531TTG No mutation/531TTG 
R72 NEG NEG NEG NEG ND ND No pattern 
R84 NEG NEG NEG NEG ND ND No pattern 
R66 PSC 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R90 NEG 3wk Sc R E O K I S ND No mutation No mutation 
R70 PSC 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R61 PSC 1wk Sc E S O K I R No mutation No mutation No mutation 
R87 P>20 3wk Sc E S O K I R No mutation No mutation/531TTG 531TTG 
R111 NEG NEG NEG NEG ND ND No mutation 
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R118 NEG NEG NEG NEG ND ND 516GTC 
R85 NEG 4wk Sc I R E S O K  ND No mutation No mutation 
R71 NEG NEG NEG NEG ND ND No pattern 
R124 PSC NEG NEG NEG ND ND No pattern 
R64 PSC 4wk Sc E O K I R S 531TTG 531TTG 531TTG 
R136 NEG NEG NEG NEG ND ND No pattern 
R94 NEG 4wk Sc E O K I R S 516GTC 516GTC 516GTC 
R116 PSC 6wk + E S O K I R 526TAC 526TAC 526TAC 
R141 P1-10 1wk Sc E O K I R S 516TAC 516TAC 516TAC 
R62 P1-10 1wk Sc E S O I R K No mutation No mutation 533CCG  
R138 P11-20 2wk ++ E S O K I R 531TTG 531TTG No 
mutation/526GAC/531TTG 
R67 PSC 1wk Sc E O K I R S No mutation No mutation 531TTG 
R148? NEG NEG NEG NEG ND No mutation No mutation 
R143 P1-10 2wk Sc E S O K I R 531TTG 531TTG 531TTG 
R120 NEG NEG NEG NEG ND ND No pattern 
R82 NEG NEG NEG NEG ND ND No pattern 
R92 NEG NEG NEG NEG ND ND No pattern 
R68 NEG NEG NEG NEG ND ND No pattern 
R137 P1-10 2wk Sc E S O K I R 516GTC 516GTC 516GTC 
R65 P>20 1wk Sc E O K I R S 516GTC 516GTC 516GTC 
R144 P>20 1wk Sc S O K I R E ND 511CCG/516GGC 511CCG/516GGC 
R109 PSC 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R117 PSC 1wk Sc E O K I R S No mutation No 
mutation/526GAC/531TTG 
531TTG 
R147 NEG NEG NEG NEG ND ND No pattern 
 179 
R132 NEG 2wk Sc I R E S O K  No mutation No mutation No mutation 
R69 PSC 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R122 PSC Contaminated Contaminated  ND ND 531TTG 
R140 NEG 3wk Sc E O S K I R 531TTG 531TTG No pattern 
R89 NEG NEG NEG NEG ND ND No pattern 
R145 P>20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R135 P11-20 NEG NEG NEG ND ND 531TTG 
R123 NEG 2wk Sc E O S K I R 533CCG 533CCG 533CCG 
R133 NEG NEG NEG NEG ND ND No pattern 
R81 NEG NEG NEG NEG ND ND No mutation 
R139 NEG 2wk Sc E O K I R S 516GTC 516GTC 516GTC 
R80 NEG NEG NEG NEG ND ND No pattern 
R108 P>20 1wk + E S O K I R 533CCG 533CCG 533CCG 
R142 NEG NEG NEG NEG ND ND No pattern 
R121 PSC 1wk Sc R E S I O K ND 533CCG 533CCG 
R83 P11-20 6wk + E O K I R S 531TTG 531TTG 531TTG 
R113 NEG 2wk Sc E O K I R S 531TTG 531TTG No mutation 
R119 NEG NEG NEG NEG ND ND No pattern 
R112 NEG NEG NEG NEG ND ND No pattern 
R110 NEG NEG NEG NEG ND ND No pattern 
R93 NEG NEG NEG NEG ND ND No pattern 
R115 NEG NEG NEG NEG ND ND 516GTC 
R159 NEG 4wk Sc MOTT MOTT ND ND No pattern 
R205 NEG NEG NEG NEG ND ND 526TAC 
R214 P11-20 2wk Sc E O K I R S 531TTG 531TTG No pattern 
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R154 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R161 NEG NEG NEG NEG ND ND No pattern 
R213 P>20 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R216 P11-20 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R223 P>20 2wk Sc E S O K I R 531TTG 531TTG 531TTG 
R232 P>20 1wk +++ E O K I R S 531TTG 531TTG 531TTG 
R149 PSC 1wk Sc E O K I R S No mutation 531TTG 531TTG 
R237 P>20 2wk Sc E S O K I R No mutation No mutation  No mutation 
R155? PSC NEG NEG NEG ND No mutation 511CCG 
R229 NEG NEG NEG NEG ND ND No pattern 
R242 P11-20 4wk + E O K I R S 531TTG 531TTG 531TTG 
R156 P>20 NEG NEG NEG ND ND 531TTG 
R219 PSC 3wk Sc I R E O K S ND 526GAC No pattern 
R211 P11-20 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R208 P>20 1wk Sc E S K I R O 526TAC 526TAC 531TTG 
R225 P11-20 2wk Sc E O K I R S 516GTC 516GTC No pattern 
R157 P11-20 1wk Sc E S O K I R 533CCG 533CCG 533CCG 
R240 NEG NEG NEG NEG ND ND No pattern 
R163 PSC 1wk Sc R E S O K I ND 516GTC 516GTC 
R212 NEG 2wk Sc E S I R O K 516GTC 516GTC 533CCG 
R158 NEG 4wk Sc I E S O K R ND No mutation No mutation 
R234 P11-20 2wk Sc I R E S O K  531TTG 531TTG 531TTG 
R164 P1-10 4wk Sc O K I R E S 531TTG 531TTG 531TTG 
R215 P1-10 4wk + R E S O K I ND 533CCG No pattern 
R227 PSC NEG NEG NEG ND ND 516TAC 
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R160 P1-10 4wk Sc O K I R E S 531TTG 531TTG 531TTG 
R235 NEG NEG NEG NEG ND ND No pattern 
R243 P>20 2wk Sc E S O K I R 533CCG 533CCG 533CCG 
R162 NEG 1wk Sc I E S O K R ND No mutation/516TAC 516GTC 
R257 PSC 1wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R248 P1-10 1wk Sc E O K I R S No mutation No mutation 531TTG 
R204 NEG NEG NEG NEG ND ND 531TTG 
R228 P>20 2wk Sc I R E O K S ND 531TTG 531TTG 
R210 P>20 2wk Sc E S O K I R No mutation No mutation 531TTG 
R206 NEG NEG NEG NEG ND ND 516GTC 
R221 NEG NEG NEG NEG ND ND 531TTG 
R217 NEG NEG NEG NEG ND ND 531TTG 
R207 NEG 2wk Sc E O S K I R 531TTG 531TTG 531TTG 
R220 NEG NEG NEG NEG ND ND 531TTG 
R254 P1-10 1wk Sc E O K I R S 516GTC 516GTC No mutation 
R209 P>20 2wk Sc E O K I R S 516GTC 516GTC No mutation 
R218 NEG NEG NEG NEG ND ND 531TTG 
R238 P>20 2wk Sc R E S O K I ND 533CCG 533CCG 
R222 NEG NEG NEG NEG ND ND 516GTC 
R231 PSC 3wk Sc E O K I R S 531TTG 531TTG 531TTG 
R247 NEG NEG NEG NEG ND ND No pattern 
R251 P>20 3wk++ S I R E O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R255 NEG NEG NEG NEG ND ND 526GAC 
R249 NEG NEG NEG NEG ND ND No pattern 
R224 P>20 2wk Sc E S O I R K ND 531TTG No mutation 
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R239 NEG NEG NEG NEG ND ND No pattern 
R226 P11-20 4wk Sc E O I R S K 531TTG 531TTG No pattern 
R230 NEG 3wk Sc E O S K I R 531TTG 531TTG 531TTG 
R241 PSC Contaminated NEG NEG ND ND 533CCG 
R233 P11-20 2wk Sc O K I R E S 526GAC 526GAC 526GAC 
R253 NEG 3wkSc E S I R O K 516GGC/533CCG 516GGC/533CCG 531TTG 
R256 P1-10 1wk Sc E O K I R S 516GTC 516GTC 516GTC 
R250 P1-10 1wk Sc R E O K I S ND No mutation No mutation 
R252 PSC 1wk Sc E I R S O K No mutation No mutation/516GGC 516TAC 
R273 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R258 P11-20 1wk Sc E S O K I R No mutation No mutation/516GTC 516TAC 
R283 PSC 1wk Sc E S O K I R 516GTC 516GTC 516GTC 
R259 NEG NEG NEG NEG ND ND 516GGC/533CCG 
R295 P11-20 1wk Sc E S I R O K ND 516GGC/533CCG 516GGC/533CCG 
R309 PSC 2wk Sc E S O K I R 531TTG 531TTG 531TTG 
R268 P11-20 1wk Sc O K I R E S 531TTG 531TTG 531TTG 
R271 NEG 2wk Sc E O S K I R 531TTG 531TTG 531TTG 
R300 P>20 1wk Sc  I R E S O K 531TTG 531TTG 516GGC/531TTG/533CCG 
R354 NEG 2wk Sc R E O K I S ND No mutation No mutation 
R349 P>20 2wk Sc E S O K I R No mutation No mutation No mutation 
R269 NEG 3wk Sc E O S K I R 531TTG 531TTG No pattern 
R274 P1-10 1wk Sc E S O K I R No mutation No mutation/531TTG 531TTG 
R280 NEG NEG NEG NEG ND ND No pattern 
R351 NEG 2wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG No pattern 
R285 PSC 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
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R270 NEG NEG NEG NEG ND ND No pattern 
R297 NEG NEG NEG NEG ND ND No pattern 
R310 NEG NEG NEG NEG ND ND No pattern 
R330 NEG 3wk Sc E O S K I R No mutation No mutation No mutation/531TTG 
R272 NEG NEG NEG NEG ND ND No pattern 
R276 P>20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R296 P11-20 1wk Sc E O K I R S ND 531TG 531TTG 
R308 NEG NEG NEG NEG ND ND No pattern 
R326 PSC NEG NEG NEG ND ND No mutation 
R334 P>20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R347 NEG NEG NEG NEG ND ND No pattern 
R277 P11-20 1wk Sc E O K I R S 516GTC 516GTC 516GTC 
R350 PSC 1wk Sc E O K I R S 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R353 NEG NEG NEG NEG ND ND No pattern 
R302 P>20 1wk Sc E S O K I R ND 531TTG 531TTG 
R316 NEG NEG NEG NEG ND ND No pattern 
R312 NEG NEG NEG NEG ND ND No pattern 
R332 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R338 NEG NEG NEG NEG ND ND No pattern 
R278 NEG NEG NEG NEG ND ND No pattern 
R284 NEG 2wk Sc E O S K I R 533CCG 533CCG No pattern 
R328 PSC 1wk Sc E O K I R S 531TTG 531TTG No mutation 
R337 NEG NEG NEG NEG ND ND No pattern 
R298 P>20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R279 NEG NEG NEG NEG ND ND No pattern 
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R352 PSC 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R281 NEG 2wk Sc E O S K I R 533CCG 533CCG 533CCG 
R314 NEG 2wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG No pattern 
R335 NEG NEG NEG NEG ND ND No pattern 
R282 PSC 2wk Sc E S O K I R No mutation No mutation/531TTG 531TTG 
R311 NEG NEG NEG NEG ND ND No pattern 
R299 P>20 1wk Sc E I R S O K 533CCG 531TTG/533CCG/516GGC 531TTG/533CCG/516GGC 
R329 P1-10 1wk sc R E S O K I ND No mutation 533CCG 
R317 NEG NEG NEG NEG ND ND No pattern 
R303 P11-20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R294 NEG NEG NEG NEG ND ND No pattern 
R301 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R304 NEG NEG NEG NEG ND ND No pattern 
R331 P1-10 2wk Sc R E O K I S ND No mutation No mutation 
R339 PSC 2wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R333 P1-10 1wk Sc E O K I R S ND No mutation 531TTG 
R318 NEG 2wk Sc I R E S O K  ND No mutation No mutation 
R313 NEG NEG NEG NEG ND ND No pattern 
R336 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R348 PSC 2wk Sc E O K I R S 531TTG 531TTG No pattern 
R315 NEG NEG NEG NEG ND ND No pattern 
R327 P>20 1wk Sc E O K I R S 516GTC 516GTC 516GTC 
R275 NEG NEG NEG NEG ND ND No pattern 
R381 NEG NEG NEG NEG ND ND No pattern 
R362 NEG 4wk Sc I R E S O K  ND No mutation No pattern 
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R389 PSC 1wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R413 NEG 2wk Sc E O S I R K 531TTG 531TTG 531TTG 
R443 P>20 1wk Sc O I R E S K 531TTG 531TTG 531TTG 
R432 NEG NEG NEG NEG ND ND No pattern 
R424 NEG NEG NEG NEG ND ND No pattern 
R355 NEG NEG NEG NEG ND ND No pattern 
R435 NEG NEG NEG NEG ND ND No pattern 
R374 NEG NEG NEG NEG ND ND No pattern 
R427 P>20 1wk Sc E S O K I R 531TTG 531TTG 516GGC/533CCG 
R394 P>20 1wk Sc E O K I R S ND 531TTG 531TTG 
R418 P1-10 1wk Sc Contaminated Contaminated ND ND No pattern 
R436 P>20 4wk Sc I E S O K R No mutation No mutation No mutation 
R364 P>20 1wk Sc E O K I R S 531TTG 531TTG 516GTC 
R421 NEG 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R441 NEG NEG NEG NEG ND ND No pattern 
R356 NEG NEG NEG NEG ND ND No pattern 
R385 NEG 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R430 P11-20 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R378 P11-20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R357 NEG NEG NEG NEG ND ND No pattern 
R437 NEG 1wk Sc E O S K I R 526TAC 526TAC 526TAC 
R392 NEG 1wk Sc E O S K I R 511CCG/516TAC 511CCG/516TAC 511CCG/516TAC 
R376 NEG 1wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R434 P11-20 1wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG No mutation 
R372 NEG 3wk Sc I R E S O K  ND No mutation No pattern 
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R425 P>20 1wk Sc E S O K I R 526GAC 526GAC 526GAC 
R358 NEG NEG NEG NEG ND ND No pattern 
R387 P11-20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R411 PSC 3wk I E S O K R ND ND 531TTG 
R429 NEG 1wk Sc E O S K I R No mutation No 
mutation/516GTC/531TTG 
531TTG 
R373 P>20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R433 NEG 6wk Sc R E O K I S ND ND 516GGC/533CCG 
R423 NEG NEG NEG NEG ND ND No pattern 
R363 P>20 1wk Sc E O K I R S ND No mutation 531TTG 
R442 NEG NEG NEG NEG ND ND No pattern 
R383 P>20 1wk Sc I R E S O K  No mutation No mutation 526? 
R365? NEG NEG NEG NEG ND 516GTC No pattern 
R375 P>20 1wk Sc E I R S O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R396 NEG 1wk Sc E O S K I R 531TTG 531TTG 531TTG 
R431 NEG 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R377 PSC 1wk Sc E O K I R S 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R415 P11-20 1wk Sc E S O K I R 511CCG/516TCC 511CCG/516TCC 511CCG/516TCC 
R420 P>20 1wk Sc I R E S O K  ND No mutation No mutation 
R412 NEG NEG NEG NEG ND ND No pattern 
R391 NEG 2wk Sc E S K I R O 531TTG 531TTG 531TTG 
R380 P11-20 1wk Sc E O K I R S No mutation No mutation No 
mutation/511CCG/516TCC 
R422 NEG NEG NEG NEG ND ND No pattern 
R386 P>20 1wk Sc O K I R E S 531TTG 531TTG 531TTG 
R414 PSC 1wk Sc E O K I R S ND ND 531TTG 
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R419 NEG 3wk + E O K I R S ND ND 531TTG 
R428 P11-20 1wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 531TTG 
R382 P1-10 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R395 P11-20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R417 NEG 1wk Sc E O K I R S 510CAT/516TAC 510CAT/516TAC No pattern 
R426 P11-20 1wk Sc E S O I R K 533CCG 533CCG 533CCG 
R379 NEG 3wk Sc E O S K I R 516GTC 516GTC No pattern 
R416 P1-10 2wk Sc E O K I R S ND 516GTC 531TTG 
R384 PSC 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R388 P11-20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R410 NEG NEG NEG NEG ND ND No pattern 
R393 NEG 3wk Sc R E S O K I ND 533CCG 533CCG 
R390 NEG NEG NEG NEG ND ND No pattern 
R505 NEG NEG NEG NEG ND ND No pattern 
R450 NEG NEG NEG NEG ND ND No pattern 
R516 NEG NEG NEG NEG ND ND No pattern 
R456 NEG 6wk Sc I E S O K R ND 526GAC No pattern 
R444 PSC 3wk Sc E S O K I R ND No mutation No pattern 
R524 NEG 2wk Sc E O K I R S 531TTG 531TTG 531TTG 
R502 P11-20 1wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG 516GGC/533CCG 
R483 NEG NEG NEG NEG ND ND No pattern 
R495 NEG 1wk Sc I R E S O K  ND No mutation 516GGC/533CCG 
R446 P1-10 NEG NEG NEG ND ND No pattern 
R477 NEG NEG NEG NEG ND ND No pattern 
R520 NEG NEG NEG NEG ND ND No pattern 
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R504 NEG 3wk Sc E S I R O K 516GGC/533CCG 516GGC/533CCG No pattern 
R445 NEG NEG NEG NEG ND ND No pattern 
R466 NEG NEG NEG NEG ND ND No pattern 
R499 NEG NEG NEG NEG ND ND No pattern 
R518 NEG 3wk Sc K I R E S O ND No pattern No pattern 
R447 NEG 3wk Sc Awaiting res Awaiting res ND 516GTC 531TTG 
R491 NEG 3wk Sc E O S K I R ND 531TTG No pattern 
R522 NEG NEG NEG NEG ND ND No pattern 
R448 NEG NEG NEG NEG ND ND No pattern 
R458 P11-20 1wk Sc EOK I R S ND 533CCG 533CCG 
R507 NEG 2wk Sc S K I R E O 516GGC/533CCG 516GGC/533CCG No pattern 
R500 P1-10 2wk Sc E S O K I R 531TTG 531TTG 531TTG 
R523 NEG NEG NEG NEG ND ND 516GGC/533CCG 
R449 P1-10 3wk Sc SOK I R E ND 531TTG 531TTG 
R453 NEG NEG NEG NEG ND ND No pattern 
R473 PSC 2wk Sc E S O K I R ND 531TTG No pattern 
R514 PSC 2wk Sc K I R E S O 531TTG 531TTG 531TTG 
R451 NEG NEG NEG NEG ND ND No pattern 
R471 P11-20 1wk Sc E O K I R S 531TTG 531TTG No pattern 
R479 P11-20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R493 NEG 1wk Sc Contaminated Contaminated ND ND No pattern 
R452 P>20 1wk Sc contaminated contaminated ND ND 531TTG 
R515 NEG 2wk Sc E O K I R S ND 531TTG No pattern 
R454 NEG NEG NEG NEG ND ND No pattern 
R475 NEG NEG NEG NEG ND ND No pattern 
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R467 NEG 6wk Sc E I R S O K ND ND No pattern 
R497 P>20 1wk Sc E O K I R S ND ND 531TTG 
R481 P11-20 1wk Sc E O K R S ND ND No pattern 
R455 NEG NEG NEG NEG ND ND No pattern 
R517 NEG NEG NEG NEG ND ND No pattern 
R459 NEG 3wk Sc E O S K I R 531TTG 531TTG No pattern 
R457 P>20 1wk Sc I R E S O K  ND No mutation No pattern 
R476 PSC NEG NEG NEG ND ND 531TTG 
R521 NEG NEG NEG NEG ND ND No pattern 
R501 P11-20 1wk Sc E O K I R S 531TTG 531TTG 531TTG 
R519 NEG NEG NEG NEG ND ND No pattern 
R478 NEG NEG NEG NEG ND ND No pattern 
R506 NEG 2wk Sc E I R S O K 516GGC/533CCG 516GGC/533CCG No pattern 
R470 P11-20 Contaminated contaminated Contaminated ND ND No pattern 
R494 PSC 1wk Sc Contaminated Contaminated ND ND No pattern 
R498 PSC 1wk Sc E S O K I R 531TTG 526GAC No pattern 
R508 NEG NEG NEG NEG ND ND No pattern 
R472 P11-20 NEG NEG NEG ND ND No pattern 
R492 P>20 1wk Sc E S I R O K 531TTG 531TTG No pattern 
R503 P>20 1wk Sc E I R S O K 516GGC/533CCG 516GGC/533CCG No pattern 
R496 P>20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
R560 PSC 1wk Sc MOTT MOTT ND ND No pattern 
R568 NEG NEG NEG NEG ND ND No pattern 
R629 P1-10 1wk + E O K I R S 531TTG 531TTG No pattern 
R589 P11-20 1wk Sc E S O K I R 531TTG 531TTG 531TTG 
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R525 NEG 2wk Sc E I R S O K 516GGC/533CCG 516GGC/533CCG No pattern 
R620 NEG NEG NEG NEG ND ND No pattern 
R574 PSC 1wk Sc E O K I R S 531TTG 531TTG No pattern 
R635 P1-10 2wk Sc E O K I R S ND No 
mutation/516GTC/531TTG 
531TTG 
R614 NEG NEG NEG NEG ND ND No pattern 
R526 NEG 2wk Sc I R E S O K  ND 526? No pattern 
R627 NEG 2wk Sc E O K I R S 516GTC 516GTC No pattern 
R693 P>20 1wk + E O K I R S 531TTG 531TTG 531TTG 
R564 NEG NEG NEG NEG ND ND No pattern 
R633 NEG NEG NEG NEG ND ND No pattern 
R580 NEG 2wk Sc E O S K I R ND ND 531TTG 
R527 NEG 2wk Sc I E O K R S 531TTG 531TTG 531TTG 
R689 NEG NEG NEG NEG ND ND No pattern 
R617 P1-10 1wk Sc E O K I R S 516GTC 516GTC 531TTG 
R584 NEG NEG NEG NEG ND ND No pattern 
R577 P11-20 1wk Sc E O K I R S 531TTG 531TTG 516GTC 
R571 P>20 1wk Sc O K I R E S ND ND 531TTG 
R530 NEG NEG NEG NEG ND ND No pattern 
R624 NEG 4wk + failed to grow failed to grow ND ND No pattern 
R586 P1-10 1wk Sc Contaminated Contaminated ND ND No pattern 
R691 NEG NEG NEG NEG ND ND No pattern 
R562 P>20 2wk Sc E O K I R S ND 526TAC 526GAC 
R622 NEG 1wk Sc E O K I R S 533CCG/516GGC 533CCG No pattern 
R582 NEG 2wk Sc E O S K I R ND 531TTG 531TTG 
 191 
R572 P11-20 2wk ++ E O K I R S ND 531TTG 531TTG 
R529 P11-20 1wk Sc E O K I R S ND ND 516GGC/533CCG 
R566 NEG NEG NEG NEG ND ND No pattern 
R626 P11-20 1wk + E O K I R S 533CCG No mutation No mutation 
R616 P11-20 1wk + E O K I R S ND ND No mut/531TTG 
R585 P1-10 1wk Sc E O K I R S ND 533CCG 531TTG 
R699 NEG 2wk + I R E O K S ND ND No pattern 
R565 P1-10 2wk +++ E S O K I R ND No 
mutation/526GAC/531TTG 
531TTG 
R631 P11-20 3wk Sc E O K I R S ND ND No pattern 
R618 P1-10 1wk Sc E S O K I R ND 526GAC 526GAC 
R528 NEG NEG NEG NEG ND ND No pattern 
R615 P1-10 1wk Sc R E S O K I ND 511CCG 511CCG 
R588 P1-10 1wk Sc E S O K I R ND 531TTG No pattern 
R579 NEG NEG NEG NEG ND ND No pattern 
R573 NEG 1wk Sc MOTT MOTT ND ND No pattern 
R613 NEG 2wk Sc E O K I R S 526GAC 531TTG No pattern 
R531 PSC 1wk Sc E O K I R S ND 531TTG 531TTG 
R567 P>20 1wk Sc E O K I R S ND ND 531TTG 
R630 P1-10 1wk Sc failed to grow failed to grow ND ND 531TTG 
R619 NEG 6wk Sc O K I R E S 531TTG 531TTG No pattern 
R561 P>20 1wk Sc E O K I R S 531TTG 526TAC 526TAC 
R591 NEG 3wk Sc E O K I R S ND 511CCG No pattern 
R575 PSC 1wk + E O K I R S 516GTC 531TTG 531TTG 




R632 P11-20 3wk Sc E S O K I R ND Mut 509-514 No pattern 
R578 NEG 1wk Sc E O S K I R ND ND No pattern 
R587 P>20 1wk Sc Contaminated Contaminated ND ND No pattern 
R623 NEG 3wk Sc E S I R O K No mutation No mutation No pattern 
R576 P1-10 1wk Sc O I R E S K 531TTG 531TTG No pattern 
R581 PSC NEG NEG NEG ND ND 531TTG 
R621 P1-10 1wk Sc E O K I R S 533CCG 533CCG 531TTG 
R628 NEG 6wk + E O K I R S ND No mutation/516GTC No pattern 
R634 P>20 1wk Sc E O K I R S ND No 
mutation/516GTC/531TTG 
531TTG 
R583 P1-10 Contaminated Contaminated Contaminated ND ND No pattern 
R625 NEG NEG NEG NEG ND ND No pattern 
 
 
